Search Results: Breast Cancer (47 results)
Research Study on the Genetics of Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/317 /research-study-on-the-genetics-of-breast-cancer
Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States
We are conducting a fully-online research study to learn more about how genes affect your risk of breast cancer. No office visit is required. Participants provide consent online, answer questions online about their health and medical history, and provide DNA via a saliva sample using a pre-paid mailer through the mail. In return for participation, study participants may receive information about their genetic ancestry for free.
Personalized Vaccine With Immunotherapy for Triple Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/400 /personalized-vaccine-with-immunotherapy-for-triple-negative-breast-cancer
Treatment
Phase 1 treatment study for people with triple-negative breast cancer
This study is testing a personalized cancer vaccine designed using proteins (called neoantigens) identified from a person’s tumor.
Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study
https://www.facingourrisk.org/research-clinical-trials/study/394 /multi-cancer-detection-blood-tests-in-adults-without-cancer-vanguard-study
Prevention
A study testing two multi-cancer detection blood tests in people who do not have cancer
The Vanguard Study is looking at how multi-cancer detection (MCD) blood tests could fit into cancer screening.
Evaluating the Safety of Nipple Sparing Mastectomy in Women With a High Risk for Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/392 /evaluating-the-safety-of-nipple-sparing-mastectomy-in-women-with-a-high-risk-for-breast-cancer
Prevention
Study for people considering double mastectomy to reduce breast cancer risk
This observational study follows participants over time to better understand the long-term effects of nipple-sparing mastectomy.
Study of a Blood Test to Look for Signs of Cancer in Higher-Risk People (CHARM2)
https://www.facingourrisk.org/research-clinical-trials/study/393 /study-of-a-blood-test-to-look-for-signs-of-cancer-in-higher-risk-people-charm2
Prevention
Blood test to find cancers earlier in high-risk people
This study is looking at how well an experimental blood test works for finding cancer earlier in people who have a higher-than-average risk of cancer because of an inherited mutation. Note: This study is only open in Canada.
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
https://www.facingourrisk.org/research-clinical-trials/study/372 /using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle
Treatment
Post-treatment study to monitor for recurrence
This study is testing whether a type of blood test called a liquid biopsy can find very small amounts of cancer left in the body after treatment—before cancer shows up on scans or causes symptoms.The blood test looks for circulating tumor DNA (ctDNA), tiny pieces of cancer DNA that may be present in the bloodstream. Researchers want to learn how well this test can:
- Detect cancer recurrence early
- Predict outcomes after treatment
- Support future use of blood‑based monitoring instead of—or in addition to—imaging tests
An Early Detection and Prevention Study for People with an Increased Risk of Cancer (InAdvance)
https://www.facingourrisk.org/research-clinical-trials/study/385 /an-early-detection-and-prevention-study-for-people-with-an-increased-risk-of-cancer-inadvance
Prevention
Study for people at risk of cancer, including previvors, survivors and family members
This study collects health information and DNA samples such as blood or saliva from participants to help researchers better understand cancer risk and early detection.
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
https://www.facingourrisk.org/research-clinical-trials/study/395 /low-dose-tamoxifen-with-or-without-omega-3-fatty-acids-for-breast-cancer-risk-reduction
Prevention
Phase 2 study for overweight postmenopausal women at increased risk for breast cancer
This phase II study is testing low-dose tamoxifen, with or without high-dose omega-3 fatty acids, in postmenopausal women who are overweight or obese and at increased risk for breast cancer.
Comparing a New Drug, Palazestrant, to Standard Treatment for Advanced Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/387 /comparing-a-new-drug-palazestrant-to-standard-treatment-for-advanced-breast-cancer
Treatment
Phase 3 study for ER-positive, HER2-negative advanced or metastatic breast cancer
This study is testing palazestrant (also called OP-1250), an investigational medicine, for people with estrogen receptor-positive (ER-positive), HER2-negative advanced or metastatic breast cancer.
Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)
https://www.facingourrisk.org/research-clinical-trials/study/388 /comparing-hormone-therapy-with-and-without-chemotherapy-for-premenopausal-breast-cancer-ofset
Treatment
Phase 3 study for premenopausal, early-stage, ER positive, HER2-negative breast cancer
This phase 3 study is for premenopausal people with early-stage ER-positive/HER2-negative breast cancer. The study is testing whether adding chemotherapy after surgery to standard ovarian function suppression and endocrine (hormone) therapy can help prevent breast cancer from coming back in younger women with early-stage disease.
Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
https://www.facingourrisk.org/research-clinical-trials/study/363 /testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
This clinical trial is studying whether the combination of two targeted therapies, abemaciclib (Verzenio) and a new targeted therapy ZEN003694 (also known as ZEN-3694) can be given together safely and what dose should be used in future studies.
Study of a New Drug, Sacituzumab Tirumotecan, Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer (TroFuse-011)
https://www.facingourrisk.org/research-clinical-trials/study/359 /study-of-a-new-drug-sacituzumab-tirumotecan-given-alone-or-in-combination-with-an-immunotherapy-for-people-with-triple-negative-breast-cancer
Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer
This study is testing a new targeted therapy, sacituzumab tirumotecan, given alone or with the immunotherapy Keytruda (pembrolizumab) to treat metastatic, triple-negative breast cancer (TNBC). Keytruda is an immunotherapy that is FDA approved to treat TNBC. The goal of the study is to learn how well sacituzumab tirumotecan can cause tumors to shrink or disappear and how long that response lasts.
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300 /study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced solid tumors
The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations.
Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2
https://www.facingourrisk.org/research-clinical-trials/study/376 /using-a-parp-inhibitor-and-oral-chemotherapy-to-treat-advanced-solid-tumors-with-a-mutation-in-brca1-brca2-palb2-atm-or-chek2
Treatment
Phase 1 treatment study for metastatic solid tumors
This study is testing a new combination of two oral drugs to see if they are safe and show signs of helping people with advanced cancer whose tumors have mutations in one of these genes: BRCA1, BRCA2, PALB2, ATM, and CHEK2.
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation
https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
This research study is testing the safety and effectiveness of an investigational targeted therapy called CX‑5461. The goal is to find a safe dose and learn more about how well the drug works to treat advanced breast, ovarian, pancreatic or prostate cancers in people with certain inherited or tumor‑related gene mutations, including ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, NBN, PALB2, RAD51C, RAD51D or other mutations related to DNA repair.
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
https://www.facingourrisk.org/research-clinical-trials/study/349 /studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
EvoPAR-BR01 is studying two investigational drugs as first-line treatment for HER2-negative, HR-positive, metastatic breast cancer in people with an inherited or tumor mutation in BRCA1, BRCA2 or PALB2. Saruparib is a new PARP1 inhibitor (a type of targeted therapy). Camizestrant is an estrogen receptor degrader (a type of hormonal therapy). The study will look at different combinations of treatments to learn which combination leads to the best survival and fewest side effects.
An Online Program to Help Asian American Breast Cancer Survivors Manage Pain and Depression
https://www.facingourrisk.org/research-clinical-trials/study/352 /an-online-program-to-help-asian-american-breast-cancer-survivors-manage-pain-and-depression
Quality of Life
An online program to help Asian American breast cancer survivors manage pain and depression
This study is looking at the effectiveness of a technology-based information and coaching and support program for Asian American women who have been diagnosed with breast cancer.
Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs
https://www.facingourrisk.org/research-clinical-trials/study/350 /treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs
Treatment
Treatment study for people with advanced or metastatic solid tumors
The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor.
HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/342 /heal-abc-study-harnessing-e-mindfulness-approaches-for-living-after-breast-cancer
Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression
This study will examine mindfulness training to improve mental health and well-being in younger breast cancer survivors, also known as “HEAL-ABC.” This trial is currently enrolling young breast cancer survivors who have elevated symptoms associated with depression.
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/345 /treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
This clinical trial is studying a new combination of drugs to treat metastatic, HER2-negative or HER2-low breast cancer in people with an inherited mutation in BRCA1, BRCA2 or PALB2 or a tumor mutation in BRCA1 or BRCA2. The study is looking at whether adding a new targeted therapy drug called axatilimab to treatment with the PARP inhibitor olaparib (Lynparza) will improve outcomes in people with metastatic breast cancer.
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/344 /study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer
Treatment
Biomarker study for people with early-stage breast cancer
This is a study looking at biomarkers to predict recurrence in people with high-risk, early-stage breast cancer who are planning to undergo chemotherapy. This study will follow patients forward over a period of time to see how well the test cancer predict outcomes.
Testing a Shorter Course of Chemo- and Immunotherapy (Without Anthracycline Drugs) for People With Early-Stage Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/343 /a-study-testing-shorter-safer-chemo-immunotherapy-without-anthracycline-drugs-for-people-with-early-stage-triple-negative-breast-cancer
Treatment
Treatment study for early-stage triple-negative breast cancer
This study is testing whether a shorter course of combined chemotherapy and immunotherapy treatment—without a type of chemotherapy known as an anthracycline—works as well as the standard, longer treatment for people with early-stage triple-negative breast cancer at high risk for recurrence.
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/304 /olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
This study is for people with advanced or metastatic breast cancer, have a BRCA1 or BRCA2 genetic mutation and were previously treated with a PARP inhibitor. The study will examine how effective Olaparib in combination with Cediranib or Ceralasertib is in reducing the size of cancer and determining the length of time patients respond well to the treatment.
Study of the drug TNG260 and an Immunotherapy in Advanced Solid Tumors With a STK11 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/333 /study-of-the-drug-tng260-and-an-immunotherapy-in-advanced-solid-tumors-with-a-stk11-mutation
Treatment
This is a treatment study enrolling people with advanced or metastatic solid tumors with known STK11 mutations
The study is designed to find the safest dose of a drug called TNG260, given along with a standard dose of the immunotherapy drug pembrolizumab, in people with advanced or metastatic solid tumors and have a STK11 genetic mutation.
Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/311 /study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas.
ShareForCures®: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry
https://www.facingourrisk.org/research-clinical-trials/study/295 /shareforcures-susan-g-komens-people-powered-data-driven-breast-cancer-research-registry
Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer
Today, researchers are learning about breast cancer from a small subset of patients, who are not representative of all breast cancer patients. ShareForCures® is an online registry that offers people who have been diagnosed with breast cancer a way to participate in research by connecting information about themselves with their breast cancer diagnosis, medical records, genomics. Participation is open to anyone adult, living in the United States, and who has been diagnosed with breast cancer.
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
https://www.facingourrisk.org/research-clinical-trials/study/282 /study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.
The WISDOM Study: Women Informed to Screen Depending on Measures of Risk
https://www.facingourrisk.org/research-clinical-trials/study/45 /wisdom-study
Prevention
Genetic testing and breast cancer screening
The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram.
Studying People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )
https://www.facingourrisk.org/research-clinical-trials/study/267 /observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation
Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families
The goal of this study is to identify whether Li-Fraumini syndrome (LFS), which has a high lifetime cancer risk, has any other causes besides the TP53 mutation. The study involves people with Li-Fraumeni syndrome and people from families with Li-Fraumeni syndrome filling out questionnaires with their medical information.
A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)
https://www.facingourrisk.org/research-clinical-trials/study/271 /a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca
Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor. The study will create a registry of women at high risk of breast cancer. A registry collects data about specific populations to understand them better. This study will also look at whether an abbreviated MRI works as well as a full MRI for screening women at high risk of breast cancer.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262 /tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Self -Perception and Intimacy After the Cancer Experience (SPICE)
https://www.facingourrisk.org/research-clinical-trials/study/247 /self-perception-and-intimacy-after-the-cancer-experience-spice
Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health
SPICE is an online survey that asks questions about your sexuality, sexual health knowledge, interpersonal relationships, and body image. Participants will be asked questions about their body image, impact of cancer, relationships, and how they feel about their sexuality.
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230 /treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Treatment
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
Helping Latinas Understand Their Risk for Breast Cancer and Get Breast Cancer Care
https://www.facingourrisk.org/research-clinical-trials/study/250 /helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care
Prevention
Latinas with a high risk of breast cancer
This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer. The study will test ways of teaching participants about breast cancer and risk factors, comparing the current standard of care to new personal educational sessions. Bilingual and bicultural staff are available for the phone study to make the study open to both English and Spanish speakers.
Cancer Experience Registry
https://www.facingourrisk.org/research-clinical-trials/study/248 /cancer-experience-registry
Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer
Online survey for patients and caregivers focusing on multiple aspects of cancer to understand its emotional, physical, practical, and financial impact, so we can identify and address gaps in care and support.
Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells
https://www.facingourrisk.org/research-clinical-trials/study/117 /sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation
The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.
Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157 /treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
https://www.facingourrisk.org/research-clinical-trials/study/109 /blood-tests-to-measure-ovarian-reserves-in-women-with-a-brca-mutation-or-women-treated-for-early-stage-breast-cancer
Prevention
Study for premenopausal women with early-stage breast cancer and high-risk women with BRCA mutations and no evidence of breast or ovarian cancer
The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).
The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies.
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
https://www.facingourrisk.org/research-clinical-trials/study/100 /talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations
Treatment
Treatment study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation)
This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1and BRCA2 mutation to determine whether this treatment (which is already approved for germline BRCA1 and BRCA2 carriers) is effective in this population.
Genomic Services Research Program Study for People with Unexpected Genetic Results
https://www.facingourrisk.org/research-clinical-trials/study/89 /study-for-people-with-unexpected-genetic-results
Prevention
Study for people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason
A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.
This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job (TEAMWork Study)
https://www.facingourrisk.org/research-clinical-trials/study/86 /talking-to-employers-and-medical-staff-about-breast-cancer-treatment-and-your-job
Quality of Life
Study for people diagnosed with cancer to help them navigate wok-related issues
The goal of this study is to improve a tool that helps cancer patients navigate work-related issues. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs. The app – called TEAMWork (Talking to Employers And Medical staff about Work) – provides advice for patients who need to talk to their employers about treatment or their medical team about work. Researchers want patient feedback on what aspects of the app work well and what can be better.
Energetics and Lifestyle in Inherited Syndromes (ELLIE’s Study)
https://www.facingourrisk.org/research-clinical-trials/study/84 /ellies-project
Quality of Life
A survey for people with a hereditary cancer genetic mutation
ELLIE’s Project is designed to look at factors that may affect cancer risk in people with inherited mutations linked to cancer. The study will look at weight, Body Mass Index, metabolism, dietary habits and activity level over the course of people’s life-time. ELLIE’s Project aims to gain a better understanding of the baseline lifestyle factors related to nutrition and physical activity in people with a hereditary cancer gene mutation.
Study for Women at Increased Risk of Developing Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/257 /study-for-women-at-increased-risk-of-developing-breast-cancer
This study will create a system to assess an individual’s risk of breast cancer
This study will create a system to assess an individual’s risk of breast cancer based on random sampling of normal breast tissue as well as determine new and help understand previously identified risk biomarkers.
Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer
https://www.facingourrisk.org/research-clinical-trials/study/223 /factors-influencing-disparities-in-quality-of-life-among-people-of-color-affected-by-cancer
Survey for people of color who have completed treatment for cancer
This study focuses on cancer survivors’ needs during the transition into a new normal life after the completion of cancer treatment. The goal is to explore ways in which we can improve physical activity and diet among cancer survivors and address their challenges to develop and maintain an active and healthy lifestyle.
We specifically would like to work with and for cancer survivors who self-describe as people of color to understand how social structures, stress and environmental factors impact health behaviors and subsequent quality of life.
RESTORE: A virtual study comparing 2 digital apps to improve mental and physical well-being of patients with stage I – 3 cancer
https://www.facingourrisk.org/research-clinical-trials/study/192 /restore-a-virtual-study-comparing-2-digital-apps-to-improve-mental-and-physical-well-being-of-patients-with-stage-i-3-cancer
People with stage 1-3 cancer
Many cancer patients experience cancer-related distress, which includes psychological symptoms of anxiety and depression. The RESTORE study will enroll up to 415 adults who have been diagnosed with stage I-III cancer. The goal is to test how effective two different apps are at improving physical and mental health. Participants use their smartphone or tablet to download and access their assigned treatment app without ever needing to visit a clinic in person.
PHACT Study: Population Health and Cancer Testing
https://www.facingourrisk.org/research-clinical-trials/study/75 /phact-study
NOTE: The PHACT study is no longer recruiting patients.
Making Genetic Testing Accessible (MAGENTA)
https://www.facingourrisk.org/research-clinical-trials/study/27 /making-genetic-testing-accessible-magenta
The goal of this research study is to test the effects of online genetic education alone or in combination with telephone genetic counseling in order to compare the two methods and the stress a person feels about their risk of cancer. NOTE: This study has closed for enrollment.
Additional Results on Clinicaltrials.gov Breast Cancer
929 results
Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
NCT ID: NCT06153836 (https://clinicaltrials.gov/study/NCT06153836)
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
NCT ID: NCT07432633 (https://clinicaltrials.gov/study/NCT07432633)
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT ID: NCT05183126 (https://clinicaltrials.gov/study/NCT05183126)
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
NCT ID: NCT05417308 (https://clinicaltrials.gov/study/NCT05417308)
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT ID: NCT05932862 (https://clinicaltrials.gov/study/NCT05932862)
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT ID: NCT05238922 (https://clinicaltrials.gov/study/NCT05238922)
Improving Genetic Counseling for BRCA+ Mothers
NCT ID: NCT04258280 (https://clinicaltrials.gov/study/NCT04258280)
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
NCT ID: NCT03418961 (https://clinicaltrials.gov/study/NCT03418961)
E-Mindfulness Approaches for Living After Breast Cancer
NCT ID: NCT06748222 (https://clinicaltrials.gov/study/NCT06748222)
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT ID: NCT06767462 (https://clinicaltrials.gov/study/NCT06767462)
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
NCT ID: NCT03740256 (https://clinicaltrials.gov/study/NCT03740256)
Cancer Pain Management Using a Web-based Intervention
NCT ID: NCT06085313 (https://clinicaltrials.gov/study/NCT06085313)
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT ID: NCT05983432 (https://clinicaltrials.gov/study/NCT05983432)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT ID: NCT05334069 (https://clinicaltrials.gov/study/NCT05334069)
Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients
NCT ID: NCT02772367 (https://clinicaltrials.gov/study/NCT02772367)
HER-2 B Cell Peptide Vaccine
NCT ID: NCT06414733 (https://clinicaltrials.gov/study/NCT06414733)
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
NCT ID: NCT05977036 (https://clinicaltrials.gov/study/NCT05977036)
Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT ID: NCT03804944 (https://clinicaltrials.gov/study/NCT03804944)
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
NCT ID: NCT04968964 (https://clinicaltrials.gov/study/NCT04968964)
Microbiome and Association With Implant Infections
NCT ID: NCT05020574 (https://clinicaltrials.gov/study/NCT05020574)
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
NCT ID: NCT06428682 (https://clinicaltrials.gov/study/NCT06428682)
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT ID: NCT03452774 (https://clinicaltrials.gov/study/NCT03452774)
A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer
NCT ID: NCT06813053 (https://clinicaltrials.gov/study/NCT06813053)
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT ID: NCT07205822 (https://clinicaltrials.gov/study/NCT07205822)
The COMPASSION Study
NCT ID: NCT06507930 (https://clinicaltrials.gov/study/NCT06507930)
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT ID: NCT06500455 (https://clinicaltrials.gov/study/NCT06500455)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://clinicaltrials.gov/study/NCT05086692)
THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation
NCT ID: NCT06395506 (https://clinicaltrials.gov/study/NCT06395506)
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT ID: NCT05964504 (https://clinicaltrials.gov/study/NCT05964504)
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT ID: NCT06312176 (https://clinicaltrials.gov/study/NCT06312176)
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT ID: NCT05508906 (https://clinicaltrials.gov/study/NCT05508906)
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
NCT ID: NCT06831838 (https://clinicaltrials.gov/study/NCT06831838)
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT ID: NCT05524584 (https://clinicaltrials.gov/study/NCT05524584)
FES BPET-DBT in Newly Diagnosed Breast Cancer
NCT ID: NCT05659797 (https://clinicaltrials.gov/study/NCT05659797)
Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
NCT ID: NCT07166042 (https://clinicaltrials.gov/study/NCT07166042)
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
NCT ID: NCT07459673 (https://clinicaltrials.gov/study/NCT07459673)
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment
NCT ID: NCT06291324 (https://clinicaltrials.gov/study/NCT06291324)
Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response
NCT ID: NCT04134780 (https://clinicaltrials.gov/study/NCT04134780)
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
NCT ID: NCT05394259 (https://clinicaltrials.gov/study/NCT05394259)
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
NCT ID: NCT06580002 (https://clinicaltrials.gov/study/NCT06580002)
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT ID: NCT05870579 (https://clinicaltrials.gov/study/NCT05870579)
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
NCT ID: NCT06374459 (https://clinicaltrials.gov/study/NCT06374459)
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05464810 (https://clinicaltrials.gov/study/NCT05464810)
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
NCT ID: NCT06185205 (https://clinicaltrials.gov/study/NCT06185205)
The Immune System's Response to Young Women's Breast Cancer
NCT ID: NCT01503190 (https://clinicaltrials.gov/study/NCT01503190)
Lifting More Than Weights: Resistance Exercise Program Across Socioeconomic Groups for Cancer-Related Fatigue Management
NCT ID: NCT06960720 (https://clinicaltrials.gov/study/NCT06960720)
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
NCT ID: NCT05877859 (https://clinicaltrials.gov/study/NCT05877859)
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
NCT ID: NCT03536897 (https://clinicaltrials.gov/study/NCT03536897)
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT ID: NCT06418204 (https://clinicaltrials.gov/study/NCT06418204)
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
NCT ID: NCT05780814 (https://clinicaltrials.gov/study/NCT05780814)
Implementation and Effectiveness of the BJC-Pink and Pearl Project on Lung Cancer Screening
NCT ID: NCT06898333 (https://clinicaltrials.gov/study/NCT06898333)
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT ID: NCT06926868 (https://clinicaltrials.gov/study/NCT06926868)
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT ID: NCT06065748 (https://clinicaltrials.gov/study/NCT06065748)
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT ID: NCT03488693 (https://clinicaltrials.gov/study/NCT03488693)
Familial Investigations of Childhood Cancer Predisposition
NCT ID: NCT03050268 (https://clinicaltrials.gov/study/NCT03050268)
Individuals on Hormone Therapy Breast Cancer Screening Pilot
NCT ID: NCT06383026 (https://clinicaltrials.gov/study/NCT06383026)
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT05318469 (https://clinicaltrials.gov/study/NCT05318469)
Magnetic Resonance Imaging of Breast Cancer
NCT ID: NCT01035112 (https://clinicaltrials.gov/study/NCT01035112)
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT07112053 (https://clinicaltrials.gov/study/NCT07112053)
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
NCT ID: NCT07055854 (https://clinicaltrials.gov/study/NCT07055854)
Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
NCT ID: NCT07387445 (https://clinicaltrials.gov/study/NCT07387445)
High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)
NCT ID: NCT03954431 (https://clinicaltrials.gov/study/NCT03954431)
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT ID: NCT03213041 (https://clinicaltrials.gov/study/NCT03213041)
ERAS Protocols in Breast Conserving Surgery
NCT ID: NCT06938581 (https://clinicaltrials.gov/study/NCT06938581)
Older Breast Cancer Patients: Risk for Cognitive Decline
NCT ID: NCT03451383 (https://clinicaltrials.gov/study/NCT03451383)
Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs
NCT ID: NCT06559059 (https://clinicaltrials.gov/study/NCT06559059)
Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes
NCT ID: NCT03396341 (https://clinicaltrials.gov/study/NCT03396341)
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT ID: NCT06926920 (https://clinicaltrials.gov/study/NCT06926920)
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
NCT ID: NCT05483283 (https://clinicaltrials.gov/study/NCT05483283)
Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients
NCT ID: NCT05612100 (https://clinicaltrials.gov/study/NCT05612100)
Cognitive Rehabilitation Following Breast Cancer Treatment
NCT ID: NCT06545045 (https://clinicaltrials.gov/study/NCT06545045)
Breast Cancer Study Tracking Risk Awareness of Alcohol Consumption and Improving Knowledge in Young Adult Women
NCT ID: NCT07320664 (https://clinicaltrials.gov/study/NCT07320664)
Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction
NCT ID: NCT07209436 (https://clinicaltrials.gov/study/NCT07209436)
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT ID: NCT07114601 (https://clinicaltrials.gov/study/NCT07114601)
SLV-154 Treatment of Metastatic Solid Tumors
NCT ID: NCT06771219 (https://clinicaltrials.gov/study/NCT06771219)
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03606967 (https://clinicaltrials.gov/study/NCT03606967)
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
NCT ID: NCT07483307 (https://clinicaltrials.gov/study/NCT07483307)
Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT ID: NCT04494945 (https://clinicaltrials.gov/study/NCT04494945)
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT ID: NCT05770531 (https://clinicaltrials.gov/study/NCT05770531)
TRUDI: TDXD+Durva in HER2+/Low IBC
NCT ID: NCT05795101 (https://clinicaltrials.gov/study/NCT05795101)
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT ID: NCT03936478 (https://clinicaltrials.gov/study/NCT03936478)
A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
NCT ID: NCT07291414 (https://clinicaltrials.gov/study/NCT07291414)
Preparing FIM-BCS - A Lifestyle Modification for African-American Breast Cancer Survivors
NCT ID: NCT06504914 (https://clinicaltrials.gov/study/NCT06504914)
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
NCT ID: NCT06260033 (https://clinicaltrials.gov/study/NCT06260033)
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
NCT ID: NCT05595499 (https://clinicaltrials.gov/study/NCT05595499)
EMBRACE: Exercising Together
NCT ID: NCT06049355 (https://clinicaltrials.gov/study/NCT06049355)
Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)
NCT ID: NCT04985032 (https://clinicaltrials.gov/study/NCT04985032)
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://clinicaltrials.gov/study/NCT04329065)
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
NCT ID: NCT07011654 (https://clinicaltrials.gov/study/NCT07011654)
The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors
NCT ID: NCT06938555 (https://clinicaltrials.gov/study/NCT06938555)
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
NCT ID: NCT03769415 (https://clinicaltrials.gov/study/NCT03769415)
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT ID: NCT05735080 (https://clinicaltrials.gov/study/NCT05735080)
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
NCT ID: NCT07017673 (https://clinicaltrials.gov/study/NCT07017673)
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
NCT ID: NCT06444269 (https://clinicaltrials.gov/study/NCT06444269)
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NCT ID: NCT06781983 (https://clinicaltrials.gov/study/NCT06781983)
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
NCT ID: NCT05766891 (https://clinicaltrials.gov/study/NCT05766891)
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT ID: NCT05325632 (https://clinicaltrials.gov/study/NCT05325632)
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT06460298 (https://clinicaltrials.gov/study/NCT06460298)
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
NCT ID: NCT04305834 (https://clinicaltrials.gov/study/NCT04305834)
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT ID: NCT06778863 (https://clinicaltrials.gov/study/NCT06778863)
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
NCT ID: NCT01441089 (https://clinicaltrials.gov/study/NCT01441089)
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT ID: NCT04891068 (https://clinicaltrials.gov/study/NCT04891068)
A Study of a Decision Tool for People Considering Breast Reconstruction Surgery
NCT ID: NCT07335354 (https://clinicaltrials.gov/study/NCT07335354)
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT ID: NCT05902988 (https://clinicaltrials.gov/study/NCT05902988)
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT ID: NCT06380751 (https://clinicaltrials.gov/study/NCT06380751)
Self-Determination Theory-informed Occupational Therapy Program to Increase Physical Activity Among Survivors of Breast Cancer
NCT ID: NCT06671730 (https://clinicaltrials.gov/study/NCT06671730)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://clinicaltrials.gov/study/NCT04550494)
Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC
NCT ID: NCT07216495 (https://clinicaltrials.gov/study/NCT07216495)
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT ID: NCT07361562 (https://clinicaltrials.gov/study/NCT07361562)
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT ID: NCT06242470 (https://clinicaltrials.gov/study/NCT06242470)
[18F] F-GLN by PET/CT in Breast Cancer
NCT ID: NCT03863457 (https://clinicaltrials.gov/study/NCT03863457)
Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
NCT ID: NCT07001241 (https://clinicaltrials.gov/study/NCT07001241)
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
NCT ID: NCT06445738 (https://clinicaltrials.gov/study/NCT06445738)
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT ID: NCT06428396 (https://clinicaltrials.gov/study/NCT06428396)
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
NCT ID: NCT07038785 (https://clinicaltrials.gov/study/NCT07038785)
Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning
NCT ID: NCT07023887 (https://clinicaltrials.gov/study/NCT07023887)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT ID: NCT03412877 (https://clinicaltrials.gov/study/NCT03412877)
Adaptation of a Values Assessment Tool
NCT ID: NCT07068477 (https://clinicaltrials.gov/study/NCT07068477)
Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery
NCT ID: NCT06297265 (https://clinicaltrials.gov/study/NCT06297265)
Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer
NCT ID: NCT04913064 (https://clinicaltrials.gov/study/NCT04913064)
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
NCT ID: NCT06144164 (https://clinicaltrials.gov/study/NCT06144164)
Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance
NCT ID: NCT07087691 (https://clinicaltrials.gov/study/NCT07087691)
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
NCT ID: NCT05297734 (https://clinicaltrials.gov/study/NCT05297734)
Integrated Cancer Repository for Cancer Research
NCT ID: NCT02012699 (https://clinicaltrials.gov/study/NCT02012699)
Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
NCT ID: NCT07207564 (https://clinicaltrials.gov/study/NCT07207564)
TNBC Gut Microbiota During Neoadjuvant Treatment
NCT ID: NCT06610097 (https://clinicaltrials.gov/study/NCT06610097)
24GUT540 : Meeting of Breast Cancer Patients and Pathologists
NCT ID: NCT07040514 (https://clinicaltrials.gov/study/NCT07040514)
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
NCT ID: NCT06105684 (https://clinicaltrials.gov/study/NCT06105684)
Preoperative Nicotine Cessation for Women With Breast Cancer Recommended for Reconstruction
NCT ID: NCT06461650 (https://clinicaltrials.gov/study/NCT06461650)
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
NCT ID: NCT00451022 (https://clinicaltrials.gov/study/NCT00451022)
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
NCT ID: NCT07555210 (https://clinicaltrials.gov/study/NCT07555210)
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
NCT ID: NCT04169542 (https://clinicaltrials.gov/study/NCT04169542)
Biennial CEM in Women With a Personal History of Breast Cancer
NCT ID: NCT06105749 (https://clinicaltrials.gov/study/NCT06105749)
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
NCT ID: NCT06371768 (https://clinicaltrials.gov/study/NCT06371768)
CBD for Breast Cancer Primary Tumors
NCT ID: NCT06148038 (https://clinicaltrials.gov/study/NCT06148038)
BREAST Choice Decision Tool R21 - AIM2
NCT ID: NCT06817226 (https://clinicaltrials.gov/study/NCT06817226)
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
NCT ID: NCT05590949 (https://clinicaltrials.gov/study/NCT05590949)
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT ID: NCT06999187 (https://clinicaltrials.gov/study/NCT06999187)
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
NCT ID: NCT06405828 (https://clinicaltrials.gov/study/NCT06405828)
SMP-3124LP in Adults With Advanced Solid Tumors
NCT ID: NCT06526819 (https://clinicaltrials.gov/study/NCT06526819)
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
NCT ID: NCT06856499 (https://clinicaltrials.gov/study/NCT06856499)
A Study of Language Interpretation Solutions for People With Breast Cancer
NCT ID: NCT06721065 (https://clinicaltrials.gov/study/NCT06721065)
A Multicenter Cancer Biospecimen Collection Study
NCT ID: NCT04510129 (https://clinicaltrials.gov/study/NCT04510129)
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
NCT ID: NCT07327489 (https://clinicaltrials.gov/study/NCT07327489)
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
NCT ID: NCT06764940 (https://clinicaltrials.gov/study/NCT06764940)
Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer
NCT ID: NCT06217874 (https://clinicaltrials.gov/study/NCT06217874)
Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors
NCT ID: NCT07436078 (https://clinicaltrials.gov/study/NCT07436078)
Definitive Radiation Therapy for Inoperable Breast Cancer
NCT ID: NCT07122713 (https://clinicaltrials.gov/study/NCT07122713)
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
NCT ID: NCT07214662 (https://clinicaltrials.gov/study/NCT07214662)
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study
NCT ID: NCT04371913 (https://clinicaltrials.gov/study/NCT04371913)
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
NCT ID: NCT02945579 (https://clinicaltrials.gov/study/NCT02945579)
Comprehensive Outcomes for After Cancer Health
NCT ID: NCT05349227 (https://clinicaltrials.gov/study/NCT05349227)
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
NCT ID: NCT07276880 (https://clinicaltrials.gov/study/NCT07276880)
CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer
NCT ID: NCT06915168 (https://clinicaltrials.gov/study/NCT06915168)
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
NCT ID: NCT05484973 (https://clinicaltrials.gov/study/NCT05484973)
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT ID: NCT07213791 (https://clinicaltrials.gov/study/NCT07213791)
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
NCT ID: NCT06582615 (https://clinicaltrials.gov/study/NCT06582615)
VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients
NCT ID: NCT06878547 (https://clinicaltrials.gov/study/NCT06878547)
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT ID: NCT06016738 (https://clinicaltrials.gov/study/NCT06016738)
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
NCT ID: NCT05959291 (https://clinicaltrials.gov/study/NCT05959291)
Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
NCT ID: NCT05754749 (https://clinicaltrials.gov/study/NCT05754749)
Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors
NCT ID: NCT04526587 (https://clinicaltrials.gov/study/NCT04526587)
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT ID: NCT06103864 (https://clinicaltrials.gov/study/NCT06103864)
Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients
NCT ID: NCT05064098 (https://clinicaltrials.gov/study/NCT05064098)
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
NCT ID: NCT03096418 (https://clinicaltrials.gov/study/NCT03096418)
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
NCT ID: NCT07214610 (https://clinicaltrials.gov/study/NCT07214610)
Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
NCT ID: NCT03897270 (https://clinicaltrials.gov/study/NCT03897270)
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT ID: NCT02422641 (https://clinicaltrials.gov/study/NCT02422641)
A 3D-Printed External Breast Prosthesis for the Improvement of Patient-reported Outcomes Among Breast Cancer Patients That Underwent a Mastectomy Without Reconstruction
NCT ID: NCT07047872 (https://clinicaltrials.gov/study/NCT07047872)
CONFIRM: Magnetic Resonance Guided Radiation Therapy
NCT ID: NCT04368702 (https://clinicaltrials.gov/study/NCT04368702)
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
NCT ID: NCT05933395 (https://clinicaltrials.gov/study/NCT05933395)
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT ID: NCT07222267 (https://clinicaltrials.gov/study/NCT07222267)
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT ID: NCT04573231 (https://clinicaltrials.gov/study/NCT04573231)
Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)
NCT ID: NCT07319195 (https://clinicaltrials.gov/study/NCT07319195)
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT ID: NCT06395519 (https://clinicaltrials.gov/study/NCT06395519)
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT ID: NCT06686394 (https://clinicaltrials.gov/study/NCT06686394)
Cardiometabolic Screening Program
NCT ID: NCT05386719 (https://clinicaltrials.gov/study/NCT05386719)
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT ID: NCT05315700 (https://clinicaltrials.gov/study/NCT05315700)
Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
NCT ID: NCT04861077 (https://clinicaltrials.gov/study/NCT04861077)
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT ID: NCT06841354 (https://clinicaltrials.gov/study/NCT06841354)
Factors Associated With Breast Cancer Risks and Outcomes
NCT ID: NCT07294703 (https://clinicaltrials.gov/study/NCT07294703)
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
NCT ID: NCT06305312 (https://clinicaltrials.gov/study/NCT06305312)
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT ID: NCT07060807 (https://clinicaltrials.gov/study/NCT07060807)
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT ID: NCT06026657 (https://clinicaltrials.gov/study/NCT06026657)
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
NCT ID: NCT04020575 (https://clinicaltrials.gov/study/NCT04020575)
Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
NCT ID: NCT06106477 (https://clinicaltrials.gov/study/NCT06106477)
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT ID: NCT06760637 (https://clinicaltrials.gov/study/NCT06760637)
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
NCT ID: NCT06409390 (https://clinicaltrials.gov/study/NCT06409390)
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
NCT ID: NCT04890613 (https://clinicaltrials.gov/study/NCT04890613)
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
NCT ID: NCT05625659 (https://clinicaltrials.gov/study/NCT05625659)
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT ID: NCT06952803 (https://clinicaltrials.gov/study/NCT06952803)
Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue
NCT ID: NCT06127797 (https://clinicaltrials.gov/study/NCT06127797)
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT ID: NCT04222413 (https://clinicaltrials.gov/study/NCT04222413)
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT ID: NCT02476786 (https://clinicaltrials.gov/study/NCT02476786)
Prospective Screening for Breast Cancer-related Lymphedema
NCT ID: NCT01521741 (https://clinicaltrials.gov/study/NCT01521741)
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT ID: NCT03463954 (https://clinicaltrials.gov/study/NCT03463954)
Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
NCT ID: NCT07066189 (https://clinicaltrials.gov/study/NCT07066189)
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
NCT ID: NCT07064018 (https://clinicaltrials.gov/study/NCT07064018)
Breast Mesh Used in Two-staged Breast Reconstruction
NCT ID: NCT04967976 (https://clinicaltrials.gov/study/NCT04967976)
Identifying Patterns in the Breath of Individuals With Breast Cancer
NCT ID: NCT06512350 (https://clinicaltrials.gov/study/NCT06512350)
Utility of a Mobile Application for Young Women With Breast Cancer
NCT ID: NCT07009093 (https://clinicaltrials.gov/study/NCT07009093)
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
NCT ID: NCT05967533 (https://clinicaltrials.gov/study/NCT05967533)
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
NCT ID: NCT05774678 (https://clinicaltrials.gov/study/NCT05774678)
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
NCT ID: NCT07408089 (https://clinicaltrials.gov/study/NCT07408089)
Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer
NCT ID: NCT06123988 (https://clinicaltrials.gov/study/NCT06123988)
Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy
NCT ID: NCT06953245 (https://clinicaltrials.gov/study/NCT06953245)
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
NCT ID: NCT03524430 (https://clinicaltrials.gov/study/NCT03524430)
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
NCT ID: NCT06176261 (https://clinicaltrials.gov/study/NCT06176261)
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
NCT ID: NCT04872166 (https://clinicaltrials.gov/study/NCT04872166)
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT ID: NCT04588545 (https://clinicaltrials.gov/study/NCT04588545)
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
NCT ID: NCT07360314 (https://clinicaltrials.gov/study/NCT07360314)
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT ID: NCT02977468 (https://clinicaltrials.gov/study/NCT02977468)
Study of Screening Brain MRIs in Stage IV Breast Cancer
NCT ID: NCT05115474 (https://clinicaltrials.gov/study/NCT05115474)
Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes
NCT ID: NCT02749474 (https://clinicaltrials.gov/study/NCT02749474)
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT ID: NCT04075305 (https://clinicaltrials.gov/study/NCT04075305)
Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
NCT ID: NCT06123286 (https://clinicaltrials.gov/study/NCT06123286)
A Prospective Study of Video-assisted Exercise Program for the Breast Cancer Survivors
NCT ID: NCT07071896 (https://clinicaltrials.gov/study/NCT07071896)
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT ID: NCT07007559 (https://clinicaltrials.gov/study/NCT07007559)
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
NCT ID: NCT03643861 (https://clinicaltrials.gov/study/NCT03643861)
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
NCT ID: NCT05837455 (https://clinicaltrials.gov/study/NCT05837455)
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
NCT ID: NCT06220214 (https://clinicaltrials.gov/study/NCT06220214)
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
NCT ID: NCT05716893 (https://clinicaltrials.gov/study/NCT05716893)
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
NCT ID: NCT07076485 (https://clinicaltrials.gov/study/NCT07076485)
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
NCT ID: NCT06439693 (https://clinicaltrials.gov/study/NCT06439693)
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT ID: NCT05935384 (https://clinicaltrials.gov/study/NCT05935384)
Neoadjuvant Breast Cancer Time Restricted Eating
NCT ID: NCT05327608 (https://clinicaltrials.gov/study/NCT05327608)
Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)
NCT ID: NCT06885203 (https://clinicaltrials.gov/study/NCT06885203)
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
NCT ID: NCT04799535 (https://clinicaltrials.gov/study/NCT04799535)
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
NCT ID: NCT06058650 (https://clinicaltrials.gov/study/NCT06058650)
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
NCT ID: NCT06139107 (https://clinicaltrials.gov/study/NCT06139107)
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
NCT ID: NCT05890677 (https://clinicaltrials.gov/study/NCT05890677)
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT ID: NCT05877599 (https://clinicaltrials.gov/study/NCT05877599)
Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
NCT ID: NCT06559540 (https://clinicaltrials.gov/study/NCT06559540)
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
NCT ID: NCT06434064 (https://clinicaltrials.gov/study/NCT06434064)
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
NCT ID: NCT06637306 (https://clinicaltrials.gov/study/NCT06637306)
An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial
NCT ID: NCT06999798 (https://clinicaltrials.gov/study/NCT06999798)
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
NCT ID: NCT06760507 (https://clinicaltrials.gov/study/NCT06760507)
Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairment in Breast and Gynecological Cancer Patients
NCT ID: NCT07173101 (https://clinicaltrials.gov/study/NCT07173101)
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT ID: NCT05607004 (https://clinicaltrials.gov/study/NCT05607004)
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT ID: NCT04389632 (https://clinicaltrials.gov/study/NCT04389632)
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
NCT ID: NCT04115306 (https://clinicaltrials.gov/study/NCT04115306)
Bundled Cancer Screening and Genetic Services Navigation
NCT ID: NCT07228000 (https://clinicaltrials.gov/study/NCT07228000)
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors
NCT ID: NCT06028022 (https://clinicaltrials.gov/study/NCT06028022)
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT ID: NCT05774951 (https://clinicaltrials.gov/study/NCT05774951)
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
NCT ID: NCT06954337 (https://clinicaltrials.gov/study/NCT06954337)
Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer
NCT ID: NCT05984888 (https://clinicaltrials.gov/study/NCT05984888)
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
NCT ID: NCT05074290 (https://clinicaltrials.gov/study/NCT05074290)
Brain Health in Breast Cancer Survivors
NCT ID: NCT04297020 (https://clinicaltrials.gov/study/NCT04297020)
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
NCT ID: NCT06515470 (https://clinicaltrials.gov/study/NCT06515470)
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
NCT ID: NCT07402473 (https://clinicaltrials.gov/study/NCT07402473)
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
NCT ID: NCT05304962 (https://clinicaltrials.gov/study/NCT05304962)
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
NCT ID: NCT04174742 (https://clinicaltrials.gov/study/NCT04174742)
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
NCT ID: NCT05005403 (https://clinicaltrials.gov/study/NCT05005403)
CTNNA1 Familial Expansion Study
NCT ID: NCT05126290 (https://clinicaltrials.gov/study/NCT05126290)
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT ID: NCT05351424 (https://clinicaltrials.gov/study/NCT05351424)
EXoPERT EMERALD Clinical Study
NCT ID: NCT07186296 (https://clinicaltrials.gov/study/NCT07186296)
Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
NCT ID: NCT06966388 (https://clinicaltrials.gov/study/NCT06966388)
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT ID: NCT07100106 (https://clinicaltrials.gov/study/NCT07100106)
Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon
NCT ID: NCT07264790 (https://clinicaltrials.gov/study/NCT07264790)
Rutgers University Study of the Genetics of Breast Cancer.
NCT ID: NCT06773897 (https://clinicaltrials.gov/study/NCT06773897)
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://clinicaltrials.gov/study/NCT05150691)
Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
NCT ID: NCT07014618 (https://clinicaltrials.gov/study/NCT07014618)
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
NCT ID: NCT06075810 (https://clinicaltrials.gov/study/NCT06075810)
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
NCT ID: NCT04389281 (https://clinicaltrials.gov/study/NCT04389281)
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT ID: NCT05130801 (https://clinicaltrials.gov/study/NCT05130801)
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT ID: NCT04886531 (https://clinicaltrials.gov/study/NCT04886531)
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT ID: NCT05696626 (https://clinicaltrials.gov/study/NCT05696626)
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
NCT ID: NCT06218303 (https://clinicaltrials.gov/study/NCT06218303)
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT ID: NCT03604315 (https://clinicaltrials.gov/study/NCT03604315)
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
NCT ID: NCT06450873 (https://clinicaltrials.gov/study/NCT06450873)
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT ID: NCT06827236 (https://clinicaltrials.gov/study/NCT06827236)
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT ID: NCT04373564 (https://clinicaltrials.gov/study/NCT04373564)
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT ID: NCT05035836 (https://clinicaltrials.gov/study/NCT05035836)
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
NCT ID: NCT05559164 (https://clinicaltrials.gov/study/NCT05559164)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT ID: NCT07517198 (https://clinicaltrials.gov/study/NCT07517198)
The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts
NCT ID: NCT05667532 (https://clinicaltrials.gov/study/NCT05667532)
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05785741 (https://clinicaltrials.gov/study/NCT05785741)
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT ID: NCT05095207 (https://clinicaltrials.gov/study/NCT05095207)
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT ID: NCT06253871 (https://clinicaltrials.gov/study/NCT06253871)
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT ID: NCT04606446 (https://clinicaltrials.gov/study/NCT04606446)
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT ID: NCT03909282 (https://clinicaltrials.gov/study/NCT03909282)
A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Breast Cancer
NCT ID: NCT07218250 (https://clinicaltrials.gov/study/NCT07218250)
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
NCT ID: NCT06731894 (https://clinicaltrials.gov/study/NCT06731894)
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT ID: NCT06239194 (https://clinicaltrials.gov/study/NCT06239194)
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
NCT ID: NCT06518057 (https://clinicaltrials.gov/study/NCT06518057)
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
NCT ID: NCT06534125 (https://clinicaltrials.gov/study/NCT06534125)
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT ID: NCT05458674 (https://clinicaltrials.gov/study/NCT05458674)
3D Ultrasound Breast Imaging
NCT ID: NCT04692818 (https://clinicaltrials.gov/study/NCT04692818)
Perioperative Mindfulness Proposal
NCT ID: NCT04049214 (https://clinicaltrials.gov/study/NCT04049214)
Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
NCT ID: NCT06974604 (https://clinicaltrials.gov/study/NCT06974604)
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT ID: NCT04641247 (https://clinicaltrials.gov/study/NCT04641247)
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
NCT ID: NCT06062498 (https://clinicaltrials.gov/study/NCT06062498)
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
NCT ID: NCT05703178 (https://clinicaltrials.gov/study/NCT05703178)
Community-led Navigation to Address Disparities in Mammography Among Native American Women
NCT ID: NCT06957535 (https://clinicaltrials.gov/study/NCT06957535)
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT ID: NCT04038619 (https://clinicaltrials.gov/study/NCT04038619)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://clinicaltrials.gov/study/NCT05269381)
Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer
NCT ID: NCT05787834 (https://clinicaltrials.gov/study/NCT05787834)
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT ID: NCT06157892 (https://clinicaltrials.gov/study/NCT06157892)
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
NCT ID: NCT04703244 (https://clinicaltrials.gov/study/NCT04703244)
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT ID: NCT05378464 (https://clinicaltrials.gov/study/NCT05378464)
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
NCT ID: NCT05218044 (https://clinicaltrials.gov/study/NCT05218044)
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT ID: NCT06638307 (https://clinicaltrials.gov/study/NCT06638307)
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT ID: NCT04981119 (https://clinicaltrials.gov/study/NCT04981119)
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT ID: NCT06586957 (https://clinicaltrials.gov/study/NCT06586957)
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT ID: NCT06995898 (https://clinicaltrials.gov/study/NCT06995898)
WashU DIEP Flap Video and Patient Understanding Improvement
NCT ID: NCT06864754 (https://clinicaltrials.gov/study/NCT06864754)
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT ID: NCT06657222 (https://clinicaltrials.gov/study/NCT06657222)
Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses
NCT ID: NCT06171607 (https://clinicaltrials.gov/study/NCT06171607)
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
NCT ID: NCT02732171 (https://clinicaltrials.gov/study/NCT02732171)
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
NCT ID: NCT05029999 (https://clinicaltrials.gov/study/NCT05029999)
Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer
NCT ID: NCT07357298 (https://clinicaltrials.gov/study/NCT07357298)
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT ID: NCT07189871 (https://clinicaltrials.gov/study/NCT07189871)
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT ID: NCT03053193 (https://clinicaltrials.gov/study/NCT03053193)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT ID: NCT06982521 (https://clinicaltrials.gov/study/NCT06982521)
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT ID: NCT06618287 (https://clinicaltrials.gov/study/NCT06618287)
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT ID: NCT05534438 (https://clinicaltrials.gov/study/NCT05534438)
Breast Cancer PSMA PET
NCT ID: NCT06586047 (https://clinicaltrials.gov/study/NCT06586047)
A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New York
NCT ID: NCT06833255 (https://clinicaltrials.gov/study/NCT06833255)
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
NCT ID: NCT06435351 (https://clinicaltrials.gov/study/NCT06435351)
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
NCT ID: NCT01000883 (https://clinicaltrials.gov/study/NCT01000883)
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
NCT ID: NCT06042569 (https://clinicaltrials.gov/study/NCT06042569)
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
NCT ID: NCT07198724 (https://clinicaltrials.gov/study/NCT07198724)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT ID: NCT06943521 (https://clinicaltrials.gov/study/NCT06943521)
NearWave Optical Molecular Monitoring
NCT ID: NCT06744465 (https://clinicaltrials.gov/study/NCT06744465)
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
NCT ID: NCT05504707 (https://clinicaltrials.gov/study/NCT05504707)
Safe and Explainable AI
NCT ID: NCT06694181 (https://clinicaltrials.gov/study/NCT06694181)
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
NCT ID: NCT06635980 (https://clinicaltrials.gov/study/NCT06635980)
Reiki Breast Surgery QOL Project for Women Undergoing Breast Surgery
NCT ID: NCT06524895 (https://clinicaltrials.gov/study/NCT06524895)
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
NCT ID: NCT05130606 (https://clinicaltrials.gov/study/NCT05130606)
Optimizing Surgical Decisions in Young Adults With Breast Cancer
NCT ID: NCT06275126 (https://clinicaltrials.gov/study/NCT06275126)
All-extremity Exercise During Breast Cancer Chemotherapy
NCT ID: NCT04914663 (https://clinicaltrials.gov/study/NCT04914663)
Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)
NCT ID: NCT06868238 (https://clinicaltrials.gov/study/NCT06868238)
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
NCT ID: NCT06008275 (https://clinicaltrials.gov/study/NCT06008275)
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
NCT ID: NCT04523857 (https://clinicaltrials.gov/study/NCT04523857)
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
NCT ID: NCT06072807 (https://clinicaltrials.gov/study/NCT06072807)
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT ID: NCT07062965 (https://clinicaltrials.gov/study/NCT07062965)
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
NCT ID: NCT07120100 (https://clinicaltrials.gov/study/NCT07120100)
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT ID: NCT05579366 (https://clinicaltrials.gov/study/NCT05579366)
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
NCT ID: NCT06268665 (https://clinicaltrials.gov/study/NCT06268665)
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
NCT ID: NCT07158164 (https://clinicaltrials.gov/study/NCT07158164)
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
NCT ID: NCT05716516 (https://clinicaltrials.gov/study/NCT05716516)
ETHAN - ET for Male BC
NCT ID: NCT05501704 (https://clinicaltrials.gov/study/NCT05501704)
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
NCT ID: NCT06700070 (https://clinicaltrials.gov/study/NCT06700070)
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
NCT ID: NCT04959474 (https://clinicaltrials.gov/study/NCT04959474)
The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients
NCT ID: NCT07341503 (https://clinicaltrials.gov/study/NCT07341503)
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
NCT ID: NCT05627960 (https://clinicaltrials.gov/study/NCT05627960)
Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy
NCT ID: NCT07137871 (https://clinicaltrials.gov/study/NCT07137871)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
NCT ID: NCT07285044 (https://clinicaltrials.gov/study/NCT07285044)
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
NCT ID: NCT06903468 (https://clinicaltrials.gov/study/NCT06903468)
Multi-center MRD Registry for Inflammatory Breast Cancer
NCT ID: NCT06966050 (https://clinicaltrials.gov/study/NCT06966050)
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
NCT ID: NCT00899301 (https://clinicaltrials.gov/study/NCT00899301)
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NCT ID: NCT06500481 (https://clinicaltrials.gov/study/NCT06500481)
Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction
NCT ID: NCT07546331 (https://clinicaltrials.gov/study/NCT07546331)
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
NCT ID: NCT03321045 (https://clinicaltrials.gov/study/NCT03321045)
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT ID: NCT03723928 (https://clinicaltrials.gov/study/NCT03723928)
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT ID: NCT06188520 (https://clinicaltrials.gov/study/NCT06188520)
Focused Ultrasound and Gemcitabine in Breast Cancer
NCT ID: NCT04796220 (https://clinicaltrials.gov/study/NCT04796220)
Global Cardio Oncology Registry
NCT ID: NCT05598879 (https://clinicaltrials.gov/study/NCT05598879)
DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer
NCT ID: NCT04766190 (https://clinicaltrials.gov/study/NCT04766190)
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT ID: NCT01766297 (https://clinicaltrials.gov/study/NCT01766297)
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
NCT ID: NCT07310420 (https://clinicaltrials.gov/study/NCT07310420)
Palbociclib and Pembrolizumab In Central Nervous System Metastases
NCT ID: NCT02896335 (https://clinicaltrials.gov/study/NCT02896335)
Precise Oncology Interventions in Nutrition and Training (OnPoint)
NCT ID: NCT06534918 (https://clinicaltrials.gov/study/NCT06534918)
SHAPE Neoadjuvant Chemotherapy Response
NCT ID: NCT04715958 (https://clinicaltrials.gov/study/NCT04715958)
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT ID: NCT07145255 (https://clinicaltrials.gov/study/NCT07145255)
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
NCT ID: NCT04458532 (https://clinicaltrials.gov/study/NCT04458532)
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
NCT ID: NCT07025785 (https://clinicaltrials.gov/study/NCT07025785)
Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
NCT ID: NCT04603209 (https://clinicaltrials.gov/study/NCT04603209)
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
NCT ID: NCT07383649 (https://clinicaltrials.gov/study/NCT07383649)
Avera Cancer Sequencing and Analytics Protocol (ASAP)
NCT ID: NCT05142033 (https://clinicaltrials.gov/study/NCT05142033)
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT ID: NCT04677816 (https://clinicaltrials.gov/study/NCT04677816)
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
NCT ID: NCT06130826 (https://clinicaltrials.gov/study/NCT06130826)
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
NCT ID: NCT05187832 (https://clinicaltrials.gov/study/NCT05187832)
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
NCT ID: NCT07259304 (https://clinicaltrials.gov/study/NCT07259304)
Weight Management After Cancer for Survivors in Rural Communities
NCT ID: NCT07426952 (https://clinicaltrials.gov/study/NCT07426952)
LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy
NCT ID: NCT05366699 (https://clinicaltrials.gov/study/NCT05366699)
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT ID: NCT05020860 (https://clinicaltrials.gov/study/NCT05020860)
Breast Elasticity Imaging During Neoadjuvant Chemotherapy
NCT ID: NCT04824027 (https://clinicaltrials.gov/study/NCT04824027)
Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout®
NCT ID: NCT05825482 (https://clinicaltrials.gov/study/NCT05825482)
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT ID: NCT04683679 (https://clinicaltrials.gov/study/NCT04683679)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT ID: NCT05879926 (https://clinicaltrials.gov/study/NCT05879926)
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT ID: NCT07488676 (https://clinicaltrials.gov/study/NCT07488676)
Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer
NCT ID: NCT05746325 (https://clinicaltrials.gov/study/NCT05746325)
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
NCT ID: NCT05563220 (https://clinicaltrials.gov/study/NCT05563220)
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
NCT ID: NCT07227077 (https://clinicaltrials.gov/study/NCT07227077)
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
NCT ID: NCT02610439 (https://clinicaltrials.gov/study/NCT02610439)
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
NCT ID: NCT05941507 (https://clinicaltrials.gov/study/NCT05941507)
Testing a Mammography Decision Intervention in a Rural Setting
NCT ID: NCT06522568 (https://clinicaltrials.gov/study/NCT06522568)
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
NCT ID: NCT02610426 (https://clinicaltrials.gov/study/NCT02610426)
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
NCT ID: NCT05514717 (https://clinicaltrials.gov/study/NCT05514717)
Time Restricted Eating During Chemotherapy for Breast Cancer
NCT ID: NCT05259410 (https://clinicaltrials.gov/study/NCT05259410)
Refining Local-Regional Therapy for IBC
NCT ID: NCT04636710 (https://clinicaltrials.gov/study/NCT04636710)
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT ID: NCT05412225 (https://clinicaltrials.gov/study/NCT05412225)
Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
NCT ID: NCT03995082 (https://clinicaltrials.gov/study/NCT03995082)
Prospective Analysis of EnVisio Spatial Intelligence for Soft Tissue Localization and Guided Surgical Excision
NCT ID: NCT06572410 (https://clinicaltrials.gov/study/NCT06572410)
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT ID: NCT02830724 (https://clinicaltrials.gov/study/NCT02830724)
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
NCT ID: NCT06099769 (https://clinicaltrials.gov/study/NCT06099769)
3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer
NCT ID: NCT05704283 (https://clinicaltrials.gov/study/NCT05704283)
PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients
NCT ID: NCT06610539 (https://clinicaltrials.gov/study/NCT06610539)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT ID: NCT06760819 (https://clinicaltrials.gov/study/NCT06760819)
MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick
NCT ID: NCT05968157 (https://clinicaltrials.gov/study/NCT05968157)
Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening
NCT ID: NCT07219277 (https://clinicaltrials.gov/study/NCT07219277)
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://clinicaltrials.gov/study/NCT04090567)
taVNS for Breast Cancer Pain and Symptom Management
NCT ID: NCT07500012 (https://clinicaltrials.gov/study/NCT07500012)
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
NCT ID: NCT04904757 (https://clinicaltrials.gov/study/NCT04904757)
Role of the Immune Environment in Response to Therapy in Breast Cancer
NCT ID: NCT05396612 (https://clinicaltrials.gov/study/NCT05396612)
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
NCT ID: NCT06517212 (https://clinicaltrials.gov/study/NCT06517212)
Definitive Radiation for High-Risk Spine Metastases
NCT ID: NCT06165419 (https://clinicaltrials.gov/study/NCT06165419)
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
NCT ID: NCT05649072 (https://clinicaltrials.gov/study/NCT05649072)
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
NCT ID: NCT05677802 (https://clinicaltrials.gov/study/NCT05677802)
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
NCT ID: NCT06910761 (https://clinicaltrials.gov/study/NCT06910761)
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
NCT ID: NCT00823654 (https://clinicaltrials.gov/study/NCT00823654)
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
NCT ID: NCT03824145 (https://clinicaltrials.gov/study/NCT03824145)
A Novel Approach Utilizing Organ Specific Age Proteomics
NCT ID: NCT06789653 (https://clinicaltrials.gov/study/NCT06789653)
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
NCT ID: NCT04144023 (https://clinicaltrials.gov/study/NCT04144023)
F-Tryptophan PET/CT in Human Cancers
NCT ID: NCT05556473 (https://clinicaltrials.gov/study/NCT05556473)
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://clinicaltrials.gov/study/NCT04771520)
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
NCT ID: NCT04150042 (https://clinicaltrials.gov/study/NCT04150042)
Postoperative Outcomes and Patient Satisfaction With Mayo Clinic Florida Care Hotel After Mastectomy and Tissue Expander Placement
NCT ID: NCT06783179 (https://clinicaltrials.gov/study/NCT06783179)
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT ID: NCT05969860 (https://clinicaltrials.gov/study/NCT05969860)
Promoting Active Living Among People With Metastatic Breast Cancer
NCT ID: NCT07238023 (https://clinicaltrials.gov/study/NCT07238023)
Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients
NCT ID: NCT06672497 (https://clinicaltrials.gov/study/NCT06672497)
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
NCT ID: NCT07222215 (https://clinicaltrials.gov/study/NCT07222215)
Study of 18F-FFNP Breast PET/MRI
NCT ID: NCT06086704 (https://clinicaltrials.gov/study/NCT06086704)
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT ID: NCT04315233 (https://clinicaltrials.gov/study/NCT04315233)
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT ID: NCT04174352 (https://clinicaltrials.gov/study/NCT04174352)
Genomic Services Research Program
NCT ID: NCT02595957 (https://clinicaltrials.gov/study/NCT02595957)
Cancer Genetic Testing in Ethnic Populations
NCT ID: NCT04475640 (https://clinicaltrials.gov/study/NCT04475640)
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT ID: NCT04768426 (https://clinicaltrials.gov/study/NCT04768426)
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT ID: NCT07109726 (https://clinicaltrials.gov/study/NCT07109726)
With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
NCT ID: NCT05721976 (https://clinicaltrials.gov/study/NCT05721976)
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
NCT ID: NCT04965064 (https://clinicaltrials.gov/study/NCT04965064)
Core Biopsies for Establishing a Breast Tumor Tissue Repository
NCT ID: NCT02250352 (https://clinicaltrials.gov/study/NCT02250352)
African Cancer Genome: GMD
NCT ID: NCT05754658 (https://clinicaltrials.gov/study/NCT05754658)
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
NCT ID: NCT00991094 (https://clinicaltrials.gov/study/NCT00991094)
Axelopran for Advanced Cancer in Patients Receiving Opioids
NCT ID: NCT07354919 (https://clinicaltrials.gov/study/NCT07354919)
A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
NCT ID: NCT06350500 (https://clinicaltrials.gov/study/NCT06350500)
Study of XB010 in Subjects With Solid Tumors
NCT ID: NCT06545331 (https://clinicaltrials.gov/study/NCT06545331)
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT ID: NCT01042379 (https://clinicaltrials.gov/study/NCT01042379)
Brodalumab in the Treatment of Immune-Related Adverse Events
NCT ID: NCT06673329 (https://clinicaltrials.gov/study/NCT06673329)
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
NCT ID: NCT06934239 (https://clinicaltrials.gov/study/NCT06934239)
GammaPod Registry and Quality of Life Nomogram
NCT ID: NCT03562273 (https://clinicaltrials.gov/study/NCT03562273)
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
NCT ID: NCT04722341 (https://clinicaltrials.gov/study/NCT04722341)
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT ID: NCT07216105 (https://clinicaltrials.gov/study/NCT07216105)
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
NCT ID: NCT05042687 (https://clinicaltrials.gov/study/NCT05042687)
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
NCT ID: NCT02918474 (https://clinicaltrials.gov/study/NCT02918474)
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT ID: NCT04485013 (https://clinicaltrials.gov/study/NCT04485013)
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT ID: NCT07115043 (https://clinicaltrials.gov/study/NCT07115043)
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
NCT ID: NCT06691035 (https://clinicaltrials.gov/study/NCT06691035)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://clinicaltrials.gov/study/NCT01174121)
Improving Care for Rural Patients With Solid Tumors
NCT ID: NCT04916990 (https://clinicaltrials.gov/study/NCT04916990)
Opioid Dispensing Device for Post-Operative Pain in Cancer Patients
NCT ID: NCT05585788 (https://clinicaltrials.gov/study/NCT05585788)
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT ID: NCT05985655 (https://clinicaltrials.gov/study/NCT05985655)
Active Surveillance in Older Women With ER+ Breast Cancer
NCT ID: NCT07262138 (https://clinicaltrials.gov/study/NCT07262138)
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT ID: NCT03694756 (https://clinicaltrials.gov/study/NCT03694756)
Circulating Tumor DNA
NCT ID: NCT06923527 (https://clinicaltrials.gov/study/NCT06923527)
Engage Psychosocial Intervention for Cancer Symptoms
NCT ID: NCT06555588 (https://clinicaltrials.gov/study/NCT06555588)
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
NCT ID: NCT06318897 (https://clinicaltrials.gov/study/NCT06318897)
Prospective Breast Cancer Biospecimen Collection
NCT ID: NCT04074720 (https://clinicaltrials.gov/study/NCT04074720)
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT ID: NCT04234386 (https://clinicaltrials.gov/study/NCT04234386)
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
NCT ID: NCT06353997 (https://clinicaltrials.gov/study/NCT06353997)
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
NCT ID: NCT06502691 (https://clinicaltrials.gov/study/NCT06502691)
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
NCT ID: NCT06827613 (https://clinicaltrials.gov/study/NCT06827613)
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
NCT ID: NCT05846789 (https://clinicaltrials.gov/study/NCT05846789)
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
NCT ID: NCT06246968 (https://clinicaltrials.gov/study/NCT06246968)
Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer
NCT ID: NCT04362826 (https://clinicaltrials.gov/study/NCT04362826)
Patient Care Outreach, Navigation, Technology and Support 2.0
NCT ID: NCT06648278 (https://clinicaltrials.gov/study/NCT06648278)
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
NCT ID: NCT07190469 (https://clinicaltrials.gov/study/NCT07190469)
Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum
NCT ID: NCT01042548 (https://clinicaltrials.gov/study/NCT01042548)
Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
NCT ID: NCT07220135 (https://clinicaltrials.gov/study/NCT07220135)
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT ID: NCT04852887 (https://clinicaltrials.gov/study/NCT04852887)
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
NCT ID: NCT05637216 (https://clinicaltrials.gov/study/NCT05637216)
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
NCT ID: NCT06876714 (https://clinicaltrials.gov/study/NCT06876714)
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT ID: NCT05608252 (https://clinicaltrials.gov/study/NCT05608252)
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
NCT ID: NCT03011684 (https://clinicaltrials.gov/study/NCT03011684)
Pioglitazone Therapy Targeting Fatigue in Breast Cancer
NCT ID: NCT05013255 (https://clinicaltrials.gov/study/NCT05013255)
The Ohio State University (OSU) SCREEN Community Program
NCT ID: NCT06666192 (https://clinicaltrials.gov/study/NCT06666192)
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT ID: NCT05288777 (https://clinicaltrials.gov/study/NCT05288777)
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
NCT ID: NCT06399757 (https://clinicaltrials.gov/study/NCT06399757)
National Mammography Database
NCT ID: NCT01900821 (https://clinicaltrials.gov/study/NCT01900821)
Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
NCT ID: NCT04724499 (https://clinicaltrials.gov/study/NCT04724499)
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT ID: NCT07102381 (https://clinicaltrials.gov/study/NCT07102381)
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
NCT ID: NCT05183828 (https://clinicaltrials.gov/study/NCT05183828)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT06270706 (https://clinicaltrials.gov/study/NCT06270706)
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT ID: NCT03671044 (https://clinicaltrials.gov/study/NCT03671044)
MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors
NCT ID: NCT06274034 (https://clinicaltrials.gov/study/NCT06274034)
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
NCT ID: NCT04468061 (https://clinicaltrials.gov/study/NCT04468061)
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT05894239 (https://clinicaltrials.gov/study/NCT05894239)
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT ID: NCT05059444 (https://clinicaltrials.gov/study/NCT05059444)
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT ID: NCT05783622 (https://clinicaltrials.gov/study/NCT05783622)
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
NCT ID: NCT02253251 (https://clinicaltrials.gov/study/NCT02253251)
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT ID: NCT06330064 (https://clinicaltrials.gov/study/NCT06330064)
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT ID: NCT05950945 (https://clinicaltrials.gov/study/NCT05950945)
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT ID: NCT05190978 (https://clinicaltrials.gov/study/NCT05190978)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT ID: NCT05633654 (https://clinicaltrials.gov/study/NCT05633654)
Cryoablation vs Lumpectomy in T1 Breast Cancers
NCT ID: NCT05505643 (https://clinicaltrials.gov/study/NCT05505643)
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
NCT ID: NCT05535192 (https://clinicaltrials.gov/study/NCT05535192)
Increasing Germline Genetic Testing for Patients With Cancer
NCT ID: NCT07307664 (https://clinicaltrials.gov/study/NCT07307664)
Inspiratory Muscle Training in Obese Breast Cancer Survivors
NCT ID: NCT05193149 (https://clinicaltrials.gov/study/NCT05193149)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT ID: NCT05827081 (https://clinicaltrials.gov/study/NCT05827081)
Dissemination of BREASTChoice AIM1-B
NCT ID: NCT07396766 (https://clinicaltrials.gov/study/NCT07396766)
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
NCT ID: NCT00353483 (https://clinicaltrials.gov/study/NCT00353483)
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
NCT ID: NCT06336928 (https://clinicaltrials.gov/study/NCT06336928)
Video Education With Result Dependent dIsclosure
NCT ID: NCT05225428 (https://clinicaltrials.gov/study/NCT05225428)
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
NCT ID: NCT04503265 (https://clinicaltrials.gov/study/NCT04503265)
Rowing Following Breast Cancer Chemotherapy
NCT ID: NCT05848141 (https://clinicaltrials.gov/study/NCT05848141)
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT ID: NCT03808337 (https://clinicaltrials.gov/study/NCT03808337)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://clinicaltrials.gov/study/NCT05092373)
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
NCT ID: NCT05570253 (https://clinicaltrials.gov/study/NCT05570253)
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
NCT ID: NCT01788839 (https://clinicaltrials.gov/study/NCT01788839)
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
NCT ID: NCT06557057 (https://clinicaltrials.gov/study/NCT06557057)
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
NCT ID: NCT06892275 (https://clinicaltrials.gov/study/NCT06892275)
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT ID: NCT05422794 (https://clinicaltrials.gov/study/NCT05422794)
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
NCT ID: NCT06855654 (https://clinicaltrials.gov/study/NCT06855654)
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
NCT ID: NCT06252662 (https://clinicaltrials.gov/study/NCT06252662)
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
NCT ID: NCT02302742 (https://clinicaltrials.gov/study/NCT02302742)
A Study of NX-1607 in Adults With Advanced Malignancies
NCT ID: NCT05107674 (https://clinicaltrials.gov/study/NCT05107674)
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT ID: NCT03990896 (https://clinicaltrials.gov/study/NCT03990896)
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
NCT ID: NCT01530373 (https://clinicaltrials.gov/study/NCT01530373)
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
NCT ID: NCT05856773 (https://clinicaltrials.gov/study/NCT05856773)
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
NCT ID: NCT07044310 (https://clinicaltrials.gov/study/NCT07044310)
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
NCT ID: NCT06085742 (https://clinicaltrials.gov/study/NCT06085742)
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://clinicaltrials.gov/study/NCT05768139)
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://clinicaltrials.gov/study/NCT04722692)
Exercise in Metastatic Breast Cancer: EMBody
NCT ID: NCT05468034 (https://clinicaltrials.gov/study/NCT05468034)
Mirai-MRI: Validation of AI Models for Breast Cancer Risk
NCT ID: NCT07121972 (https://clinicaltrials.gov/study/NCT07121972)
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT ID: NCT06695845 (https://clinicaltrials.gov/study/NCT06695845)
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT ID: NCT06562192 (https://clinicaltrials.gov/study/NCT06562192)
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT ID: NCT06257264 (https://clinicaltrials.gov/study/NCT06257264)
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
NCT ID: NCT01185132 (https://clinicaltrials.gov/study/NCT01185132)
Breast Cancer Resiliency Through Exercise Program (B-REP)
NCT ID: NCT06100263 (https://clinicaltrials.gov/study/NCT06100263)
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
NCT ID: NCT06966453 (https://clinicaltrials.gov/study/NCT06966453)
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
NCT ID: NCT06525766 (https://clinicaltrials.gov/study/NCT06525766)
Breast Cancer Survivorship Biorepository
NCT ID: NCT05786664 (https://clinicaltrials.gov/study/NCT05786664)
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
NCT ID: NCT05406232 (https://clinicaltrials.gov/study/NCT05406232)
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT ID: NCT04333706 (https://clinicaltrials.gov/study/NCT04333706)
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
NCT ID: NCT05472792 (https://clinicaltrials.gov/study/NCT05472792)
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
NCT ID: NCT04354064 (https://clinicaltrials.gov/study/NCT04354064)
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
NCT ID: NCT02333604 (https://clinicaltrials.gov/study/NCT02333604)
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT ID: NCT05768932 (https://clinicaltrials.gov/study/NCT05768932)
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
NCT ID: NCT04997993 (https://clinicaltrials.gov/study/NCT04997993)
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT ID: NCT05837767 (https://clinicaltrials.gov/study/NCT05837767)
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
NCT ID: NCT05256745 (https://clinicaltrials.gov/study/NCT05256745)
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT ID: NCT07174336 (https://clinicaltrials.gov/study/NCT07174336)
Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors
NCT ID: NCT07032545 (https://clinicaltrials.gov/study/NCT07032545)
Effects of Chemotherapy on Cognitive Function in Breast Cancer Patients & Non-Cancer Control Subjects With Optional Sub-Study Research Brain MRI
NCT ID: NCT03137095 (https://clinicaltrials.gov/study/NCT03137095)
Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT ID: NCT04990921 (https://clinicaltrials.gov/study/NCT04990921)
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
NCT ID: NCT06749210 (https://clinicaltrials.gov/study/NCT06749210)
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT ID: NCT06577987 (https://clinicaltrials.gov/study/NCT06577987)
Physical Activity Targeting Metabolic Syndrome for Prevention of Breast Cancer in SAI Women
NCT ID: NCT06827704 (https://clinicaltrials.gov/study/NCT06827704)
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT ID: NCT04841148 (https://clinicaltrials.gov/study/NCT04841148)
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
NCT ID: NCT07140172 (https://clinicaltrials.gov/study/NCT07140172)
Improving Exercise Capacity With a Tailored Physical Activity Intervention
NCT ID: NCT05595577 (https://clinicaltrials.gov/study/NCT05595577)
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT ID: NCT06401421 (https://clinicaltrials.gov/study/NCT06401421)
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
NCT ID: NCT06774027 (https://clinicaltrials.gov/study/NCT06774027)
The MIND-BC Study: MIND Diet for Breast Cancer Cognition
NCT ID: NCT07018986 (https://clinicaltrials.gov/study/NCT07018986)
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT ID: NCT04119024 (https://clinicaltrials.gov/study/NCT04119024)
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT ID: NCT06533059 (https://clinicaltrials.gov/study/NCT06533059)
TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer
NCT ID: NCT05507879 (https://clinicaltrials.gov/study/NCT05507879)
Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial
NCT ID: NCT05379153 (https://clinicaltrials.gov/study/NCT05379153)
IKS014 in Advanced Solid Tumors That Express HER2
NCT ID: NCT05872295 (https://clinicaltrials.gov/study/NCT05872295)
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT ID: NCT04030507 (https://clinicaltrials.gov/study/NCT04030507)
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
NCT ID: NCT07340541 (https://clinicaltrials.gov/study/NCT07340541)
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
NCT ID: NCT07540572 (https://clinicaltrials.gov/study/NCT07540572)
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT ID: NCT06435429 (https://clinicaltrials.gov/study/NCT06435429)
Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming
NCT ID: NCT06536881 (https://clinicaltrials.gov/study/NCT06536881)
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT ID: NCT05366881 (https://clinicaltrials.gov/study/NCT05366881)
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
NCT ID: NCT06440005 (https://clinicaltrials.gov/study/NCT06440005)
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT ID: NCT07029399 (https://clinicaltrials.gov/study/NCT07029399)
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
NCT ID: NCT07016399 (https://clinicaltrials.gov/study/NCT07016399)
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
NCT ID: NCT06557148 (https://clinicaltrials.gov/study/NCT06557148)
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
NCT ID: NCT06238921 (https://clinicaltrials.gov/study/NCT06238921)
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT ID: NCT04895709 (https://clinicaltrials.gov/study/NCT04895709)
Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
NCT ID: NCT06802172 (https://clinicaltrials.gov/study/NCT06802172)
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
NCT ID: NCT07389967 (https://clinicaltrials.gov/study/NCT07389967)
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT ID: NCT06195306 (https://clinicaltrials.gov/study/NCT06195306)
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
NCT ID: NCT05978128 (https://clinicaltrials.gov/study/NCT05978128)
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT ID: NCT06682793 (https://clinicaltrials.gov/study/NCT06682793)
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT ID: NCT05812807 (https://clinicaltrials.gov/study/NCT05812807)
Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)
NCT ID: NCT05334732 (https://clinicaltrials.gov/study/NCT05334732)
Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT ID: NCT04563507 (https://clinicaltrials.gov/study/NCT04563507)
A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials
NCT ID: NCT05655494 (https://clinicaltrials.gov/study/NCT05655494)
Breast Cancer Implementation Science Study With Educational Intervention
NCT ID: NCT06927895 (https://clinicaltrials.gov/study/NCT06927895)
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT ID: NCT04282044 (https://clinicaltrials.gov/study/NCT04282044)
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT ID: NCT04969835 (https://clinicaltrials.gov/study/NCT04969835)
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT ID: NCT05919108 (https://clinicaltrials.gov/study/NCT05919108)
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
NCT ID: NCT05683418 (https://clinicaltrials.gov/study/NCT05683418)
Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management
NCT ID: NCT07242118 (https://clinicaltrials.gov/study/NCT07242118)
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT ID: NCT06184750 (https://clinicaltrials.gov/study/NCT06184750)
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
NCT ID: NCT07558733 (https://clinicaltrials.gov/study/NCT07558733)
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT ID: NCT07182149 (https://clinicaltrials.gov/study/NCT07182149)
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT ID: NCT06797635 (https://clinicaltrials.gov/study/NCT06797635)
Living Well With Advanced Breast Cancer
NCT ID: NCT07227038 (https://clinicaltrials.gov/study/NCT07227038)
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NCT ID: NCT05592938 (https://clinicaltrials.gov/study/NCT05592938)
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
NCT ID: NCT05178498 (https://clinicaltrials.gov/study/NCT05178498)
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
NCT ID: NCT07076147 (https://clinicaltrials.gov/study/NCT07076147)
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
NCT ID: NCT06908928 (https://clinicaltrials.gov/study/NCT06908928)
A Study of Revaree Plus in People With Breast Cancer
NCT ID: NCT07042581 (https://clinicaltrials.gov/study/NCT07042581)
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT ID: NCT05736367 (https://clinicaltrials.gov/study/NCT05736367)
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
NCT ID: NCT05245812 (https://clinicaltrials.gov/study/NCT05245812)
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
NCT ID: NCT06134375 (https://clinicaltrials.gov/study/NCT06134375)
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
NCT ID: NCT06860815 (https://clinicaltrials.gov/study/NCT06860815)
High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
NCT ID: NCT00291096 (https://clinicaltrials.gov/study/NCT00291096)
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
NCT ID: NCT06488378 (https://clinicaltrials.gov/study/NCT06488378)
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT ID: NCT06369285 (https://clinicaltrials.gov/study/NCT06369285)
The Florida ASCENT Study
NCT ID: NCT07042243 (https://clinicaltrials.gov/study/NCT07042243)
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT ID: NCT02290834 (https://clinicaltrials.gov/study/NCT02290834)
Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge
NCT ID: NCT05056844 (https://clinicaltrials.gov/study/NCT05056844)
Tumor-Derived FGF19
NCT ID: NCT06068257 (https://clinicaltrials.gov/study/NCT06068257)
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT ID: NCT06247995 (https://clinicaltrials.gov/study/NCT06247995)
Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stress (FOCUS)
NCT ID: NCT07102212 (https://clinicaltrials.gov/study/NCT07102212)
Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations Study
NCT ID: NCT07029490 (https://clinicaltrials.gov/study/NCT07029490)
Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis
NCT ID: NCT05369546 (https://clinicaltrials.gov/study/NCT05369546)
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
NCT ID: NCT03934905 (https://clinicaltrials.gov/study/NCT03934905)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://clinicaltrials.gov/study/NCT05417594)
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
NCT ID: NCT06959537 (https://clinicaltrials.gov/study/NCT06959537)
A Study of XMT-1660 in Participants With Solid Tumors
NCT ID: NCT05377996 (https://clinicaltrials.gov/study/NCT05377996)
Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
NCT ID: NCT00898131 (https://clinicaltrials.gov/study/NCT00898131)
A Study of the TheraBionic P1 Device in Breast Cancer
NCT ID: NCT07218432 (https://clinicaltrials.gov/study/NCT07218432)
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT ID: NCT06150664 (https://clinicaltrials.gov/study/NCT06150664)
ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT ID: NCT04893109 (https://clinicaltrials.gov/study/NCT04893109)
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT ID: NCT04862663 (https://clinicaltrials.gov/study/NCT04862663)
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT ID: NCT06006806 (https://clinicaltrials.gov/study/NCT06006806)
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
NCT ID: NCT04003038 (https://clinicaltrials.gov/study/NCT04003038)
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
NCT ID: NCT04084730 (https://clinicaltrials.gov/study/NCT04084730)
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
NCT ID: NCT06533826 (https://clinicaltrials.gov/study/NCT06533826)
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT ID: NCT07503808 (https://clinicaltrials.gov/study/NCT07503808)
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT ID: NCT07214532 (https://clinicaltrials.gov/study/NCT07214532)
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
NCT ID: NCT05491226 (https://clinicaltrials.gov/study/NCT05491226)
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT ID: NCT05108298 (https://clinicaltrials.gov/study/NCT05108298)
A Study of HLD-0117 in Patients With Metastatic Breast Cancer
NCT ID: NCT07524855 (https://clinicaltrials.gov/study/NCT07524855)
A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation
NCT ID: NCT06258993 (https://clinicaltrials.gov/study/NCT06258993)
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
NCT ID: NCT07137416 (https://clinicaltrials.gov/study/NCT07137416)
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT ID: NCT05309655 (https://clinicaltrials.gov/study/NCT05309655)
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
NCT ID: NCT07069595 (https://clinicaltrials.gov/study/NCT07069595)
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT ID: NCT06625775 (https://clinicaltrials.gov/study/NCT06625775)
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT ID: NCT05283330 (https://clinicaltrials.gov/study/NCT05283330)
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer
NCT ID: NCT07121244 (https://clinicaltrials.gov/study/NCT07121244)
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
NCT ID: NCT06799065 (https://clinicaltrials.gov/study/NCT06799065)
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
NCT ID: NCT06169371 (https://clinicaltrials.gov/study/NCT06169371)
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
NCT ID: NCT06245889 (https://clinicaltrials.gov/study/NCT06245889)
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
NCT ID: NCT06324240 (https://clinicaltrials.gov/study/NCT06324240)
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
NCT ID: NCT04022616 (https://clinicaltrials.gov/study/NCT04022616)
A Study of Mental Health Care in People With Cancer
NCT ID: NCT06037954 (https://clinicaltrials.gov/study/NCT06037954)
A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer
NCT ID: NCT05910294 (https://clinicaltrials.gov/study/NCT05910294)
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT ID: NCT05693766 (https://clinicaltrials.gov/study/NCT05693766)
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NCT ID: NCT05896189 (https://clinicaltrials.gov/study/NCT05896189)
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT ID: NCT05941520 (https://clinicaltrials.gov/study/NCT05941520)
Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial
NCT ID: NCT05930483 (https://clinicaltrials.gov/study/NCT05930483)
HER2 Vaccine for Locally Advanced Breast Cancer
NCT ID: NCT06949410 (https://clinicaltrials.gov/study/NCT06949410)
MADRE (Mammograms Available Due to Research and Education)
NCT ID: NCT05841355 (https://clinicaltrials.gov/study/NCT05841355)
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
NCT ID: NCT06780176 (https://clinicaltrials.gov/study/NCT06780176)
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT ID: NCT05573126 (https://clinicaltrials.gov/study/NCT05573126)
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
NCT ID: NCT05676255 (https://clinicaltrials.gov/study/NCT05676255)
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT06172478 (https://clinicaltrials.gov/study/NCT06172478)
Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery
NCT ID: NCT07206121 (https://clinicaltrials.gov/study/NCT07206121)
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
NCT ID: NCT04517838 (https://clinicaltrials.gov/study/NCT04517838)
Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
NCT ID: NCT05417867 (https://clinicaltrials.gov/study/NCT05417867)
Sacituzumab Govitecan In TNBC
NCT ID: NCT04230109 (https://clinicaltrials.gov/study/NCT04230109)
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
NCT ID: NCT06113016 (https://clinicaltrials.gov/study/NCT06113016)
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT ID: NCT05528133 (https://clinicaltrials.gov/study/NCT05528133)
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
NCT ID: NCT07071038 (https://clinicaltrials.gov/study/NCT07071038)
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
NCT ID: NCT06953882 (https://clinicaltrials.gov/study/NCT06953882)
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
NCT ID: NCT02926690 (https://clinicaltrials.gov/study/NCT02926690)
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
NCT ID: NCT07447050 (https://clinicaltrials.gov/study/NCT07447050)
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT ID: NCT03572374 (https://clinicaltrials.gov/study/NCT03572374)
A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania
NCT ID: NCT05438511 (https://clinicaltrials.gov/study/NCT05438511)
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
NCT ID: NCT06551116 (https://clinicaltrials.gov/study/NCT06551116)
SABER Study for Selected Early Stage Breast Cancer
NCT ID: NCT04360330 (https://clinicaltrials.gov/study/NCT04360330)
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
NCT ID: NCT07287995 (https://clinicaltrials.gov/study/NCT07287995)
A Study of Surgery and Radiotherapy in People With Breast Cancer
NCT ID: NCT07053085 (https://clinicaltrials.gov/study/NCT07053085)
Lymphedema Surveillance Study
NCT ID: NCT02743858 (https://clinicaltrials.gov/study/NCT02743858)
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
NCT ID: NCT07095114 (https://clinicaltrials.gov/study/NCT07095114)
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT ID: NCT06756932 (https://clinicaltrials.gov/study/NCT06756932)
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
NCT ID: NCT07203378 (https://clinicaltrials.gov/study/NCT07203378)
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT ID: NCT07020117 (https://clinicaltrials.gov/study/NCT07020117)
A Study of Blood Pressure Control During Cancer Treatment
NCT ID: NCT06023576 (https://clinicaltrials.gov/study/NCT06023576)
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT ID: NCT06582017 (https://clinicaltrials.gov/study/NCT06582017)
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
NCT ID: NCT05898399 (https://clinicaltrials.gov/study/NCT05898399)
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
NCT ID: NCT06092892 (https://clinicaltrials.gov/study/NCT06092892)
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
NCT ID: NCT05921253 (https://clinicaltrials.gov/study/NCT05921253)
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT ID: NCT06997029 (https://clinicaltrials.gov/study/NCT06997029)
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
NCT ID: NCT04434040 (https://clinicaltrials.gov/study/NCT04434040)
A Study of LY4175408 in Participants With Advanced Cancer
NCT ID: NCT07046923 (https://clinicaltrials.gov/study/NCT07046923)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://clinicaltrials.gov/study/NCT04585750)
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT ID: NCT05098210 (https://clinicaltrials.gov/study/NCT05098210)
Scalp Cooling in MBC
NCT ID: NCT04986579 (https://clinicaltrials.gov/study/NCT04986579)
Feasibility Study of CBCT for IGRT in Cancer Patients
NCT ID: NCT06681233 (https://clinicaltrials.gov/study/NCT06681233)
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT ID: NCT05467891 (https://clinicaltrials.gov/study/NCT05467891)
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
NCT ID: NCT06110793 (https://clinicaltrials.gov/study/NCT06110793)
Collection of Blood From Patients With Cancer
NCT ID: NCT00034216 (https://clinicaltrials.gov/study/NCT00034216)
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
NCT ID: NCT00477100 (https://clinicaltrials.gov/study/NCT00477100)
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
NCT ID: NCT07225114 (https://clinicaltrials.gov/study/NCT07225114)
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
NCT ID: NCT06902311 (https://clinicaltrials.gov/study/NCT06902311)
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT ID: NCT06993844 (https://clinicaltrials.gov/study/NCT06993844)
Exercise to ReGain Stamina and Energy (The EXERGISE Study)
NCT ID: NCT05684367 (https://clinicaltrials.gov/study/NCT05684367)
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
NCT ID: NCT07368998 (https://clinicaltrials.gov/study/NCT07368998)
The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
NCT ID: NCT06318507 (https://clinicaltrials.gov/study/NCT06318507)
Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy
NCT ID: NCT07386444 (https://clinicaltrials.gov/study/NCT07386444)
Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
NCT ID: NCT07231159 (https://clinicaltrials.gov/study/NCT07231159)
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT ID: NCT07524322 (https://clinicaltrials.gov/study/NCT07524322)
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
NCT ID: NCT05291507 (https://clinicaltrials.gov/study/NCT05291507)
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
NCT ID: NCT06322888 (https://clinicaltrials.gov/study/NCT06322888)
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT ID: NCT06377852 (https://clinicaltrials.gov/study/NCT06377852)
The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT ID: NCT02000089 (https://clinicaltrials.gov/study/NCT02000089)
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT07229313 (https://clinicaltrials.gov/study/NCT07229313)
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
NCT ID: NCT05146297 (https://clinicaltrials.gov/study/NCT05146297)
Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors
NCT ID: NCT06728579 (https://clinicaltrials.gov/study/NCT06728579)
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
NCT ID: NCT05206331 (https://clinicaltrials.gov/study/NCT05206331)
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
NCT ID: NCT06888388 (https://clinicaltrials.gov/study/NCT06888388)
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
NCT ID: NCT06349642 (https://clinicaltrials.gov/study/NCT06349642)
Surviving Daily Life
NCT ID: NCT07054723 (https://clinicaltrials.gov/study/NCT07054723)
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT ID: NCT05208762 (https://clinicaltrials.gov/study/NCT05208762)
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
NCT ID: NCT06678269 (https://clinicaltrials.gov/study/NCT06678269)
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
NCT ID: NCT06828588 (https://clinicaltrials.gov/study/NCT06828588)
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT ID: NCT04711824 (https://clinicaltrials.gov/study/NCT04711824)
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
NCT ID: NCT06896474 (https://clinicaltrials.gov/study/NCT06896474)
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT ID: NCT07318805 (https://clinicaltrials.gov/study/NCT07318805)
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT ID: NCT06022029 (https://clinicaltrials.gov/study/NCT06022029)
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
NCT ID: NCT05440929 (https://clinicaltrials.gov/study/NCT05440929)
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
NCT ID: NCT06471673 (https://clinicaltrials.gov/study/NCT06471673)
HER2-positive Breast Cancer Registry
NCT ID: NCT06603597 (https://clinicaltrials.gov/study/NCT06603597)
Strength After Breast Cancer
NCT ID: NCT06052488 (https://clinicaltrials.gov/study/NCT06052488)
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
NCT ID: NCT05694559 (https://clinicaltrials.gov/study/NCT05694559)
CtDNA Based MRD Testing for NAC Monitoring in TNBC
NCT ID: NCT06230185 (https://clinicaltrials.gov/study/NCT06230185)
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT ID: NCT07211178 (https://clinicaltrials.gov/study/NCT07211178)
A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials
NCT ID: NCT07040891 (https://clinicaltrials.gov/study/NCT07040891)
Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk
NCT ID: NCT07137468 (https://clinicaltrials.gov/study/NCT07137468)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT ID: NCT04802759 (https://clinicaltrials.gov/study/NCT04802759)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT ID: NCT03424005 (https://clinicaltrials.gov/study/NCT03424005)
EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer
NCT ID: NCT06115486 (https://clinicaltrials.gov/study/NCT06115486)
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
NCT ID: NCT05900895 (https://clinicaltrials.gov/study/NCT05900895)
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT ID: NCT06324357 (https://clinicaltrials.gov/study/NCT06324357)
A Study of DM001 in Patients With Advanced Solid Tumors
NCT ID: NCT06475937 (https://clinicaltrials.gov/study/NCT06475937)
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
NCT ID: NCT07311993 (https://clinicaltrials.gov/study/NCT07311993)
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
NCT ID: NCT07078604 (https://clinicaltrials.gov/study/NCT07078604)
Study of 68Ga-R10602
NCT ID: NCT06745804 (https://clinicaltrials.gov/study/NCT06745804)
Project SOAR (Speaking Our African American Realities) Awakenings for Black American Women Diagnosed With Breast Cancer
NCT ID: NCT07208084 (https://clinicaltrials.gov/study/NCT07208084)
Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer
NCT ID: NCT07506876 (https://clinicaltrials.gov/study/NCT07506876)
Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks
NCT ID: NCT06574022 (https://clinicaltrials.gov/study/NCT06574022)
A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation
NCT ID: NCT06772181 (https://clinicaltrials.gov/study/NCT06772181)
Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
NCT ID: NCT06806930 (https://clinicaltrials.gov/study/NCT06806930)
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
NCT ID: NCT06347068 (https://clinicaltrials.gov/study/NCT06347068)
A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial
NCT ID: NCT07443943 (https://clinicaltrials.gov/study/NCT07443943)
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT ID: NCT05386108 (https://clinicaltrials.gov/study/NCT05386108)
Patient Priorities for Survivorship Care in Older Breast Cancer Survivors
NCT ID: NCT06478589 (https://clinicaltrials.gov/study/NCT06478589)
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
NCT ID: NCT07308717 (https://clinicaltrials.gov/study/NCT07308717)
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
NCT ID: NCT05376878 (https://clinicaltrials.gov/study/NCT05376878)
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
NCT ID: NCT03351348 (https://clinicaltrials.gov/study/NCT03351348)
Access to Genetic Testing in Underserved Patients With Cancer
NCT ID: NCT06422455 (https://clinicaltrials.gov/study/NCT06422455)
Oral Aromatase Inhibitors Modify the Gut Microbiome
NCT ID: NCT05030038 (https://clinicaltrials.gov/study/NCT05030038)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT ID: NCT06492616 (https://clinicaltrials.gov/study/NCT06492616)
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
NCT ID: NCT05989347 (https://clinicaltrials.gov/study/NCT05989347)
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
NCT ID: NCT04348747 (https://clinicaltrials.gov/study/NCT04348747)
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT ID: NCT07478016 (https://clinicaltrials.gov/study/NCT07478016)
Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
NCT ID: NCT07227233 (https://clinicaltrials.gov/study/NCT07227233)
Breast Re-irradiation After Second Ipsilateral Lumpectomy
NCT ID: NCT06867484 (https://clinicaltrials.gov/study/NCT06867484)
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
NCT ID: NCT06085833 (https://clinicaltrials.gov/study/NCT06085833)
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT ID: NCT06784193 (https://clinicaltrials.gov/study/NCT06784193)
Improving Comprehensive Care of Cancer Patients
NCT ID: NCT05323409 (https://clinicaltrials.gov/study/NCT05323409)
Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai
NCT ID: NCT07220863 (https://clinicaltrials.gov/study/NCT07220863)
Outcomes and Cosmesis With Whole Breast Irradiation and Boost
NCT ID: NCT06295744 (https://clinicaltrials.gov/study/NCT06295744)
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT ID: NCT06058377 (https://clinicaltrials.gov/study/NCT06058377)
[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
NCT ID: NCT07020806 (https://clinicaltrials.gov/study/NCT07020806)
Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study
NCT ID: NCT07123649 (https://clinicaltrials.gov/study/NCT07123649)
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
NCT ID: NCT04521764 (https://clinicaltrials.gov/study/NCT04521764)
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT ID: NCT06757634 (https://clinicaltrials.gov/study/NCT06757634)
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT ID: NCT05824975 (https://clinicaltrials.gov/study/NCT05824975)
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT ID: NCT05787587 (https://clinicaltrials.gov/study/NCT05787587)
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT ID: NCT06072612 (https://clinicaltrials.gov/study/NCT06072612)
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05490472 (https://clinicaltrials.gov/study/NCT05490472)
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
NCT ID: NCT07220967 (https://clinicaltrials.gov/study/NCT07220967)
Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study
NCT ID: NCT03408353 (https://clinicaltrials.gov/study/NCT03408353)
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
NCT ID: NCT06954831 (https://clinicaltrials.gov/study/NCT06954831)
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT ID: NCT06239467 (https://clinicaltrials.gov/study/NCT06239467)
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT ID: NCT04614194 (https://clinicaltrials.gov/study/NCT04614194)
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT ID: NCT04923542 (https://clinicaltrials.gov/study/NCT04923542)
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT ID: NCT04553770 (https://clinicaltrials.gov/study/NCT04553770)
Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction
NCT ID: NCT05223322 (https://clinicaltrials.gov/study/NCT05223322)
Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
NCT ID: NCT06103669 (https://clinicaltrials.gov/study/NCT06103669)
Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy
NCT ID: NCT05704842 (https://clinicaltrials.gov/study/NCT05704842)
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT ID: NCT05867251 (https://clinicaltrials.gov/study/NCT05867251)
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
NCT ID: NCT06263543 (https://clinicaltrials.gov/study/NCT06263543)
A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC)
NCT ID: NCT06334354 (https://clinicaltrials.gov/study/NCT06334354)
SAVE Trial: SAfe Opioid Use Video Education
NCT ID: NCT07044583 (https://clinicaltrials.gov/study/NCT07044583)
UCF MammoChat: Image Repository
NCT ID: NCT07214883 (https://clinicaltrials.gov/study/NCT07214883)
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT ID: NCT05372640 (https://clinicaltrials.gov/study/NCT05372640)
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
NCT ID: NCT04751435 (https://clinicaltrials.gov/study/NCT04751435)
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
NCT ID: NCT05076760 (https://clinicaltrials.gov/study/NCT05076760)
Adaptive Symptom Self-Management Immunotherapy Study
NCT ID: NCT05715255 (https://clinicaltrials.gov/study/NCT05715255)
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT ID: NCT05483491 (https://clinicaltrials.gov/study/NCT05483491)
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
NCT ID: NCT06451497 (https://clinicaltrials.gov/study/NCT06451497)
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
NCT ID: NCT07158021 (https://clinicaltrials.gov/study/NCT07158021)
A Registry Study of Breast Microseed Treatment
NCT ID: NCT02701244 (https://clinicaltrials.gov/study/NCT02701244)
Survivors Uniting for Remote Guided Exercise
NCT ID: NCT07290309 (https://clinicaltrials.gov/study/NCT07290309)
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
NCT ID: NCT05455619 (https://clinicaltrials.gov/study/NCT05455619)
Exploring the Feasibility of an Exercise and Noninvasive Brain Stimulation Intervention in Breast Cancer Survivors
NCT ID: NCT07587957 (https://clinicaltrials.gov/study/NCT07587957)
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
NCT ID: NCT06845319 (https://clinicaltrials.gov/study/NCT06845319)
Saci Nivo Rela for TNBC
NCT ID: NCT06963905 (https://clinicaltrials.gov/study/NCT06963905)
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
NCT ID: NCT04606030 (https://clinicaltrials.gov/study/NCT04606030)
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
NCT ID: NCT06763328 (https://clinicaltrials.gov/study/NCT06763328)
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
NCT ID: NCT06727773 (https://clinicaltrials.gov/study/NCT06727773)
Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
NCT ID: NCT05219695 (https://clinicaltrials.gov/study/NCT05219695)
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
NCT ID: NCT06998407 (https://clinicaltrials.gov/study/NCT06998407)
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT ID: NCT04787042 (https://clinicaltrials.gov/study/NCT04787042)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://clinicaltrials.gov/study/NCT04300556)
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT ID: NCT07405801 (https://clinicaltrials.gov/study/NCT07405801)
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT ID: NCT04265872 (https://clinicaltrials.gov/study/NCT04265872)
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT ID: NCT05748834 (https://clinicaltrials.gov/study/NCT05748834)
B.Brilliant Revelation Comparision Study
NCT ID: NCT07067788 (https://clinicaltrials.gov/study/NCT07067788)
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
NCT ID: NCT00005095 (https://clinicaltrials.gov/study/NCT00005095)
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT ID: NCT07192432 (https://clinicaltrials.gov/study/NCT07192432)
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT ID: NCT05929768 (https://clinicaltrials.gov/study/NCT05929768)
ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)
NCT ID: NCT07505797 (https://clinicaltrials.gov/study/NCT07505797)
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT ID: NCT05305924 (https://clinicaltrials.gov/study/NCT05305924)
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT ID: NCT07424547 (https://clinicaltrials.gov/study/NCT07424547)
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT ID: NCT03449238 (https://clinicaltrials.gov/study/NCT03449238)
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT ID: NCT05037825 (https://clinicaltrials.gov/study/NCT05037825)
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
NCT ID: NCT06441890 (https://clinicaltrials.gov/study/NCT06441890)
Biomarkers to Detect Endocrine Therapy Resistance
NCT ID: NCT06067503 (https://clinicaltrials.gov/study/NCT06067503)
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
NCT ID: NCT05660083 (https://clinicaltrials.gov/study/NCT05660083)
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
NCT ID: NCT06795529 (https://clinicaltrials.gov/study/NCT06795529)
EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial
NCT ID: NCT06897488 (https://clinicaltrials.gov/study/NCT06897488)
IMPACT Trial: Intervention to iMProve AdherenCe Equitably
NCT ID: NCT05496829 (https://clinicaltrials.gov/study/NCT05496829)
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT ID: NCT05216432 (https://clinicaltrials.gov/study/NCT05216432)
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
NCT ID: NCT06956690 (https://clinicaltrials.gov/study/NCT06956690)
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
NCT ID: NCT06538389 (https://clinicaltrials.gov/study/NCT06538389)
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT ID: NCT07287917 (https://clinicaltrials.gov/study/NCT07287917)
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
NCT ID: NCT06127979 (https://clinicaltrials.gov/study/NCT06127979)
Quantitative MRI Assessment of Breast Cancer Therapy Response
NCT ID: NCT05704062 (https://clinicaltrials.gov/study/NCT05704062)
HIIT Following Breast Cancer Chemotherapy
NCT ID: NCT05913713 (https://clinicaltrials.gov/study/NCT05913713)
COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients
NCT ID: NCT05972343 (https://clinicaltrials.gov/study/NCT05972343)
A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer
NCT ID: NCT06327490 (https://clinicaltrials.gov/study/NCT06327490)
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
NCT ID: NCT06545682 (https://clinicaltrials.gov/study/NCT06545682)
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT ID: NCT06179303 (https://clinicaltrials.gov/study/NCT06179303)
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
NCT ID: NCT03941756 (https://clinicaltrials.gov/study/NCT03941756)
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT ID: NCT04567420 (https://clinicaltrials.gov/study/NCT04567420)
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT ID: NCT06293898 (https://clinicaltrials.gov/study/NCT06293898)
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT ID: NCT06568692 (https://clinicaltrials.gov/study/NCT06568692)
MRg-NIRS Imaging System Breast Cancer Trial
NCT ID: NCT06400563 (https://clinicaltrials.gov/study/NCT06400563)
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
NCT ID: NCT06507618 (https://clinicaltrials.gov/study/NCT06507618)
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
NCT ID: NCT06917313 (https://clinicaltrials.gov/study/NCT06917313)
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
NCT ID: NCT06961955 (https://clinicaltrials.gov/study/NCT06961955)
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT ID: NCT07288359 (https://clinicaltrials.gov/study/NCT07288359)
ILR to Prevent BRCL_MCC 23608
NCT ID: NCT07127003 (https://clinicaltrials.gov/study/NCT07127003)
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
NCT ID: NCT04650256 (https://clinicaltrials.gov/study/NCT04650256)
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT ID: NCT05746897 (https://clinicaltrials.gov/study/NCT05746897)
Susan G. Komen's ShareForCures
NCT ID: NCT05654246 (https://clinicaltrials.gov/study/NCT05654246)
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
NCT ID: NCT06075953 (https://clinicaltrials.gov/study/NCT06075953)
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT ID: NCT05557877 (https://clinicaltrials.gov/study/NCT05557877)
Study in Patients With Breast Cancer Leptomeningeal Metastasis
NCT ID: NCT06638294 (https://clinicaltrials.gov/study/NCT06638294)
Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer
NCT ID: NCT06666439 (https://clinicaltrials.gov/study/NCT06666439)
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT ID: NCT06518837 (https://clinicaltrials.gov/study/NCT06518837)
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT ID: NCT06120283 (https://clinicaltrials.gov/study/NCT06120283)
Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen
NCT ID: NCT05056857 (https://clinicaltrials.gov/study/NCT05056857)
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
NCT ID: NCT07332975 (https://clinicaltrials.gov/study/NCT07332975)
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
NCT ID: NCT07054190 (https://clinicaltrials.gov/study/NCT07054190)
Mobile Health for Adherence in Breast Cancer Patients
NCT ID: NCT06112613 (https://clinicaltrials.gov/study/NCT06112613)
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
NCT ID: NCT02610413 (https://clinicaltrials.gov/study/NCT02610413)
IDOV-Immune for Advanced Solid Tumors
NCT ID: NCT06910657 (https://clinicaltrials.gov/study/NCT06910657)
Remote Monitoring and Symptom Management Digital Application
NCT ID: NCT07553572 (https://clinicaltrials.gov/study/NCT07553572)
Evaluation of the Bexa Breast Examination
NCT ID: NCT06643767 (https://clinicaltrials.gov/study/NCT06643767)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT ID: NCT06966700 (https://clinicaltrials.gov/study/NCT06966700)
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT ID: NCT05952557 (https://clinicaltrials.gov/study/NCT05952557)
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
NCT ID: NCT06875128 (https://clinicaltrials.gov/study/NCT06875128)
Intra-Operative Radiation Registry
NCT ID: NCT04994067 (https://clinicaltrials.gov/study/NCT04994067)
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT ID: NCT04427293 (https://clinicaltrials.gov/study/NCT04427293)
Two Versus One Week Breast Radiotherapy (RT)
NCT ID: NCT06960707 (https://clinicaltrials.gov/study/NCT06960707)
A Pilot Study to Evaluate the Effectiveness of Focused Massage on Pain, Mobility, and Quality of Life During Radiation Treatment for Patients With Breast Cancer
NCT ID: NCT07447700 (https://clinicaltrials.gov/study/NCT07447700)
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT ID: NCT06249048 (https://clinicaltrials.gov/study/NCT06249048)
Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics
NCT ID: NCT05056818 (https://clinicaltrials.gov/study/NCT05056818)
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
NCT ID: NCT05463796 (https://clinicaltrials.gov/study/NCT05463796)
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
NCT ID: NCT06833502 (https://clinicaltrials.gov/study/NCT06833502)
Impact of Ketogenic Diet on Tumor Microenvironment in Patients With Breast Cancer
NCT ID: NCT07574671 (https://clinicaltrials.gov/study/NCT07574671)
BostonGene and Exigent Genomic INsight Study
NCT ID: NCT06272864 (https://clinicaltrials.gov/study/NCT06272864)
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
NCT ID: NCT06750484 (https://clinicaltrials.gov/study/NCT06750484)
Resistance Training and Post Workout Protein to Improve Body Composition During Neoadjuvant Chemotherapy for Breast Cancer
NCT ID: NCT06858449 (https://clinicaltrials.gov/study/NCT06858449)
ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction
NCT ID: NCT06981208 (https://clinicaltrials.gov/study/NCT06981208)
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
NCT ID: NCT04332588 (https://clinicaltrials.gov/study/NCT04332588)
The PREDICT Registry:
NCT ID: NCT03448926 (https://clinicaltrials.gov/study/NCT03448926)
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
NCT ID: NCT05974150 (https://clinicaltrials.gov/study/NCT05974150)
Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital
NCT ID: NCT07146568 (https://clinicaltrials.gov/study/NCT07146568)
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
NCT ID: NCT05996107 (https://clinicaltrials.gov/study/NCT05996107)
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT ID: NCT07085767 (https://clinicaltrials.gov/study/NCT07085767)
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05673200 (https://clinicaltrials.gov/study/NCT05673200)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT ID: NCT06465069 (https://clinicaltrials.gov/study/NCT06465069)
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
NCT ID: NCT06430541 (https://clinicaltrials.gov/study/NCT06430541)
A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients
NCT ID: NCT06833853 (https://clinicaltrials.gov/study/NCT06833853)
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT ID: NCT06400472 (https://clinicaltrials.gov/study/NCT06400472)
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
NCT ID: NCT05523947 (https://clinicaltrials.gov/study/NCT05523947)
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery
NCT ID: NCT04888975 (https://clinicaltrials.gov/study/NCT04888975)
Dance Study for Post-surgical Pain in Breast Cancer Survivors
NCT ID: NCT06758102 (https://clinicaltrials.gov/study/NCT06758102)
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
NCT ID: NCT05298605 (https://clinicaltrials.gov/study/NCT05298605)
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
NCT ID: NCT06055881 (https://clinicaltrials.gov/study/NCT06055881)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT ID: NCT05232916 (https://clinicaltrials.gov/study/NCT05232916)
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
NCT ID: NCT06388122 (https://clinicaltrials.gov/study/NCT06388122)
Intravital Microscopy in Human Solid Tumors
NCT ID: NCT03823144 (https://clinicaltrials.gov/study/NCT03823144)
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
NCT ID: NCT06129747 (https://clinicaltrials.gov/study/NCT06129747)
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
NCT ID: NCT07118176 (https://clinicaltrials.gov/study/NCT07118176)
Sample Collection for Ongoing Research and Product Evaluation Study
NCT ID: NCT07318051 (https://clinicaltrials.gov/study/NCT07318051)
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT ID: NCT02926729 (https://clinicaltrials.gov/study/NCT02926729)
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
NCT ID: NCT05464082 (https://clinicaltrials.gov/study/NCT05464082)
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
NCT ID: NCT06623396 (https://clinicaltrials.gov/study/NCT06623396)
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT ID: NCT07173751 (https://clinicaltrials.gov/study/NCT07173751)
UNC Pleural Fluid Registry
NCT ID: NCT05620329 (https://clinicaltrials.gov/study/NCT05620329)
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://clinicaltrials.gov/study/NCT05123482)
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
NCT ID: NCT06492759 (https://clinicaltrials.gov/study/NCT06492759)
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
NCT ID: NCT07313306 (https://clinicaltrials.gov/study/NCT07313306)
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT ID: NCT06774963 (https://clinicaltrials.gov/study/NCT06774963)
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT ID: NCT06726148 (https://clinicaltrials.gov/study/NCT06726148)
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT ID: NCT06790693 (https://clinicaltrials.gov/study/NCT06790693)
Breast Cancer, Reasoning, and Activity Intervention
NCT ID: NCT04816006 (https://clinicaltrials.gov/study/NCT04816006)
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
NCT ID: NCT06361940 (https://clinicaltrials.gov/study/NCT06361940)
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
NCT ID: NCT01034033 (https://clinicaltrials.gov/study/NCT01034033)
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT ID: NCT05868226 (https://clinicaltrials.gov/study/NCT05868226)
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
NCT ID: NCT05561842 (https://clinicaltrials.gov/study/NCT05561842)
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT ID: NCT03796559 (https://clinicaltrials.gov/study/NCT03796559)
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
NCT ID: NCT07224464 (https://clinicaltrials.gov/study/NCT07224464)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://clinicaltrials.gov/study/NCT05564377)
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT ID: NCT03729115 (https://clinicaltrials.gov/study/NCT03729115)
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
NCT ID: NCT02620852 (https://clinicaltrials.gov/study/NCT02620852)
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
NCT ID: NCT06896162 (https://clinicaltrials.gov/study/NCT06896162)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT ID: NCT06393374 (https://clinicaltrials.gov/study/NCT06393374)
Breast Cancer Screening Decision Aid
NCT ID: NCT07515846 (https://clinicaltrials.gov/study/NCT07515846)
Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
NCT ID: NCT06294574 (https://clinicaltrials.gov/study/NCT06294574)
The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment
NCT ID: NCT06096623 (https://clinicaltrials.gov/study/NCT06096623)
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
NCT ID: NCT05134779 (https://clinicaltrials.gov/study/NCT05134779)
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
NCT ID: NCT05313191 (https://clinicaltrials.gov/study/NCT05313191)
Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
NCT ID: NCT06401889 (https://clinicaltrials.gov/study/NCT06401889)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.